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        Molecular biorecognition is at the heart of all biological processes and has come to 
the center stage in designing new biologics. Coiled-coils result from molecular 
biorecognition of multiple protein α-helices. We have designed a series of coiled-coil 
motifs that self-assemble into supercoils, which in turn function as physical cross-linkers 
in the construction of hybrid biomaterials.  
        This dissertation describes our endeavors following the hypothesis below: the self-
assembly of coiled-coil forming peptides into coiled-coils can be used as a cross-linking 
mechanism in the construction of hybrid hydrogels and the development of a drug-free 
macromolecular therapeutic.  
        In the first part, a macromonomer free radical copolymerization strategy was 
developed and HPMA graft copolymers containing coiled-coil motifs of different chain 
lengths were synthesized. Results indicated that the primary structure of these motifs 
greatly influenced gel formation. At least four heptads were needed to mediate effective 
gelation. The gelation process was highly dependent on the environmental temperature 
and copolymer concentration. 
        In the second part, a drug-free macromolecular therapeutic was designed to take full 
advantage of the facts that CD20 is one of the most reliable biomarkers for B-cell non-
Hodgkin’s lymphoma (NHL), and cross-linking of CD20 antigens induces apoptosis of B 
cells. The drug-free therapeutic was composed of two components: Fab’ fragment of 1F5 
	   iv	  
anti-CD20 antibody conjugated with one coiled-coil motif (CCE) and polyHPMA 
copolymer grafted with multiple copies of the complementary coiled-coil motif (CCK). 
In vitro studies showed the conjugates could colocalize on Raji cell surfaces and a 
clinically relevant magnitude of apoptosis was achieved. A systemic NHL murine model 
was used to evaluate in vivo efficacy. Significant delay of hind-limb paralysis onset was 
observed after treatment. In groups receiving multiple-dose treatment, the surviving mice 
were disease-free and no presence of Raji B cell in bone marrow could be detected after 
100 days.  
        In summary, the possibility of integrating molecular biorecognition of short non-
natural coiled-coil motifs into new smart biomaterials is presented. This specific 
biorecognition can be used with or without adjuvant pharmacology to mediate a 
biofunctional process in combating diseases. 	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1.1. Molecular biorecognition 
        Molecular biorecognition is at the heart of all biological events (1, 2), defined as 
noncovalent forces that produce specific interactions between a biomolecule and its 
ligand, such as protein-protein (2), RNA-protein (3), and enzyme-substrate pairs (4). 
Such recognition yields the specific interactions responsible for the essential processes of 
life, including genetic information trafficking, protein folding, cellular signal 
transduction, metabolism, and others. The growing knowledge base about molecular 
biorecognition has been a great inspiration to researchers for the design of new 
biomedical systems and devices. 
        The shape and energetic complementarity of interacting surfaces governs molecular 
biorecognition. This understanding has evolved from Emil Fischer’s “key-and-lock” 
analogy in 1894 (5) to Paul Ehrlich’s stereocomplementarity (side-chain theory of 
immunity) in 1900 (6, 7), then to the modern “induced-fit” model (3, 8, 9). Although the 
essential mechanism of biorecognition remains a mystery, the major molecular level 
factors contributing to complementarity have been well identified (10). They include:  
        1. surface shapes of the interacting molecules 
        2. hydrogen bond(s) between molecules 
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        3. ion-ion, dipole-dipole and ion-dipole interactions 
        4. van der Waals forces 
        5. hydrophobic interactions  
        The far-reaching consequence of molecular biorecognition is its role at the interface 
between medicine, biology and chemistry, with manifold implications and applications 
(2, 11-13). Functioning as a key driving force, biorecognition has become a critical 
component for novel biomaterial designs, such as self-assembling materials (14) targeted 
drug delivery systems (15-17), diagnostic devices with super sensitivity (11) and novel 
smart biomaterials (18).  
  
1.2. The coiled-coil motif 
        Coiled-coils are ubiquitous protein folding patterns in nature, composed of multiple 
α-helices self-assembled into left- or right-handed supercoils; with the self-assembling 
process tightly regulated by principles of molecular biorecognition. Since the first crystal 
structures of coiled-coils were solved in the 1950s (19, 20), coiled-coil motifs have 
gained great attention and wide application (21-30). These motifs have become the most 
intensively studied protein folding motifs due to their sequence periodicity, structural 
simplicity, designability, reversible self-assembly, and stimuli-sensitivity (24). 
 
1.2.1. Coiled-coil dissection  
        The α-helix is the building block for coiled-coils, to produce the multiple helices 
wrapping around each other following the “knobs-into-holes” packing rules (31). Coiled-
coil motifs can further assemble into fibrils or other shapes driven by mainly hydrophobic 
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interactions. The typical primary sequence of the α-helix has a unique feature of seven-
amino-acid repeat – the heptad. The number of heptads in a single helix can range from 2 
in a de novo designed motif (32) to 200 in natural proteins (24). The seven amino acid 
positions of a heptad are conveniently designated as (abcdefg)n. In general, a and d 
positions are occupied by hydrophobic residues (Leu, Ile and Val); e and g positions are 
oftentimes taken by charged residues (Glu and Lys); the remaining positions are mainly 
arranged with hydrophilic residues to adjust α-helical propensity, net charge and 
solubility (33). The amino acid residue arrangement and major inter-chain interactions 
are often delineated by a helical-wheel diagram (Figure 1.1). The right-handed α-helices 
wind around the helical axis into left-handed supercoils, giving 3.5 residues per turn or 
one complete heptad after two turns (21). The critical forces driving the amphipathic 
helices forming coiled-coils are interchain hydrophobic interactions between a and d 
positions in the core and ionic interactions (salt bridges) between e and g positions. Both 
types of interactions work together to determine the coiled-coil stability and specificity 
(34, 35). Furthermore, the overall rotational and translational motions are another source 
of the driving forces unique to coiled-coils. Of course, other factors (e.g. hydrogen 
bonding) involved in molecular biorecognition apply to coiled-coil formation as well.   
        Coiled-coil specificity has three aspects: number of helices, relative orientation of 
helices and their helices oligomerization (homo- vs. hetero-) (21, 24), as demonstrated in 
Figure 1.2. In engineered coiled-coils, there can be 2, 3, 4, 5 and 7 helical strands forming 
dimer, trimer, tetramer, pentamer and heptamer associations, respectively. Same (homo-) 
or different (hetero-) helices can associate into supercoils along the same  (parallel) or 





Figure 1.1. Helical wheel diagram of a coiled-coil composed of 2 α-helices aligned in 
anti-parallel orientation. Primary sequence of the α-helix has a characteristic 7 amino acid 
repeat, the heptad. a (a’) – g (g’) are 7 amino acid positions in one heptad. Appropriate 
arrangement of amino acids is required to allow for hydrophobic core packing and ionic 
interactions: a (a’) and d (d’) positions mainly for hydrophobic residues (e.g., leucine, 
isoleucine and alanine), e (e’) and g (g’) positions for charged residues (e.g., lysine and 
glutamic acid), and the remaining positions for residues to adjust α-helical propensity, net 
charge and solubility. α-Helices wind around the helical axis into supercoils with one 





Figure 1.2. Examples of coiled-coils with different specificities: a) Parallel dimer (PDB 
entry 3MOV) (36); b) Anti-parallel trimer (PDB entry 3K7Z) (37); c) Parallel tetramer 
(PDB entry 2IPZ) (38); d) Parallel pentamer (PDB entry 2GUV) (39); e) 7-strand coiled-
coil (PDB entry 2HY6) (40). 
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Besides coiled-coils composed of heptad repeats, researchers have also confirmed the 
existence of right-handed coiled-coils consisting of 11/3 (11 residues in 3 turns), 15/4, 
18/5, and 25/7 arrangements. Conformation exchange among random coil, coiled-coil 
and β-sheet was also observed upon changing their microenvironment, such as pH (41, 
42) and addition of related biomolecules (43). Since these phenomena are beyond the 
scope of this dissertation, no detailed discussion will be given. 
 
1.2.2. De novo design of coiled-coil motifs 
        Due to its intriguing features, requirements for de novo design of coiled-coil motif 
must be elucidated to enable its further exploration for applications. Successful design of 
coiled-coil motifs lies in appropriate arrangement of residues to ensure all the key coiled-
coil interactions. Specificity of the target coiled-coil motifs may be tailor-made toward 
different purposes with a possible sacrifice of stability. 
        Since the hydrophobic interactions between a and d positions are the major driving 
forces in coiled-coil formation, the proper selection of residues at these positions is of 
critical importance for resulting specificity and stability (44, 45). Hodges’ group (46-48) 
divided 20 natural amino acids into three groups regarding their ability to determine the 
number of helices in resulting coiled-coil. The first group of amino acids impart 100% 
specificity at both a and d positions: Arg, Lys, Asp (100% two helices) and Tyr (100% 
three helices). The second group imparts 100% specificity only at one of the two 
positions: Gln, His and Leu (100% three helices at a); Ile and Val (100% three helices at 




        High resolution crystal structures of coiled-coils also revealed the residue preference 
in the hydrophobic core (31). For instance, in parallel dimeric coiled-coil a positions are 
enriched in β-branched residues Val and Ile, and d positions are abundant in γ-branched 
residue Leu. But in trimeric coiled-coil, both kinds of residues are equally represented 
and evenly distributed in a and d positions. Residue placements in other positions are also 
critical. Litowski and colleagues greatly improved the coiled-coil stability by replacing 
Ser with Ala in b positions based on the fact that Ala has a higher α-helical propensity 
(33).  
        Additionally, there are two other ways to direct helix orientations: 1) introduction of 
hydrogen bonds via placing polar residues in the hydrophobic core; 2) manipulation of 
the ionic interactions by arranging charged residues at e and g positions. Kim’s group had 
elaborated the successful control over parallel and anti-parallel orientation by 
incorporating asparagines (Asn) at a and/or d positions, although at the cost of stability 
(49-52). Hodges and coworkers succeeded in aligning helices in preferred orientations by 
adjusting the attraction and repulsion between the charged residues (Glu and Lys) at e/g-
e’/g’ positions (53-55). Moreover, they showed that the anti-parallel orientation imparted 
the highest overall stability and the minimum steric hindrance to the resulted coiled-coil 
(54). Interestingly, Okaley and colleagues (34) directed the helical orientation (anti-
parallel) by introducing Coulombic interactions between d (Arg) and g’ (Glu) positions, 
and showed that this arrangement suffered less thermodynamic cost than burying two 
Asn’s in the hydrophobic core (56). The conformation interchange between coiled-coil 
and β-sheet could also be achieved by proper sequence design, as demonstrated by 
Koksch’s group (42). Eventually the overall side-chain property (polarity, charge and 
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shape) of amino acid residues determines the final conformation of a coiled-coil and the 
subsequent folding of the whole protein (57).   
        Great effort has been expended to shorten the chain length of α-helices in order to 
minimize the synthesis workload. However, one needs to keep in mind that the helicity of 
peptides is closely related with the chain length in a cooperative manner, so are the 
coiled-coil stability and specificity (58, 59). Kay’s group reported that a minimum of 
three heptads (6 turns) was required for a stable two-stranded coiled-coil conformation 
and five or more appeared to be optimal (60). This observation was in good agreement 
with later reports (61, 62). Although one report claimed a successful design of helices 
containing only two heptads forming stable coiled-coils, the authors failed to identify the 
uniqueness of the design to allow for coiled-coil formation (32).  
        Computational methods were developed to aid the rational de novo design of coiled-
coil motifs. PairCoil and MultiCoil are multi-dimensional scoring algorithms to predict 
oligomerization state of coiled-coils (63). Another modeling method employed energy 
minimization techniques to profile the aggregation of coiled-coils (64). An open-source 
coiled-coil prediction algorithm is also available to estimate melting temperature (Tm) of 
dimeric coiled-coils as an indication for the strength of helix interactions (65-67). 
 
1.2.3. Self-assembly of coiled-coil motifs and their characterization 
         As crucial building blocks of organisms, α-helices do self-assemble into structures 
of higher orders to execute certain bio-functions. Due to the non-covalent nature of inter-
chain interactions, helices can automatically associate into supercoils or dissociate upon 
appropriate stimuli. These molecular switches may include pH, temperature, ionic 
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strength, and presence/removal of biomolecules (68). This phenomenon is called the 
stimuli-responsive self-assembly of coiled-coils. Self-assembly into coiled-coils is not 
only about helices winding into one another, but also allowing specific inter-chain 
interactions. Being “programmed” into the sequences (69), these interactions essentially 
define the relative alignment and direction of the intertwined helices. In other words, 
supercoil conformation accommodates certain systematic side-chain interactions rather 
than the bending of the axis of the α-helix (70).  
        Facilitated self-assembly of small coiled-coil motifs allows the building of supra-
molecules with well-defined structures through only noncovalent interactions (71, 72), as 
shown by our group in 1999 (22). More importantly, the self-assembling process is 
programmable and controllable, which presents many potential applications. For instance, 
the resulting materials can possess various morphologies (e.g., rod, fibril, globule, etc.) 
by design for different purposes (68, 73).    
        Different biophysical techniques were developed to “visualize” and quantify the 
self-assembly of coiled-coil motifs. The most commonly used ones are listed in Table 
1.1. Several reagents frequently employed during the analyses are: trifluoroethanol 
(TFE), guanidine hydrochloride (GndHCl) and urea. TFE can only stabilize α-helices in 
the region with high helical propensity, but not induce α-helical structure from any given 
sequence; in other words, it is considered as a helical enhancing co-solvent rather than an 
inducing agent (74). Due to their different solutropic interactions, GndHCl and urea 
promote different protein folding interactions during denaturation (53): the charged 




Table 1.1. Frequently used biophysical techniques to characterize coiled-coils.  
Techniques Description & Application References 
Circular dichroism (CD) 
spectroscopy 
Secondary structures, double minima at 





Molecular weight measurement and 





Oligomerization state monitoring (47, 48) 
GdnHCl and Urea 
denaturation 
Coiled-coil stability and interaction 
analysis 
(54) 
X-ray crystallography Crystal structure determination (75) 
Nuclear magnetic 
resonance (NMR) 
Determination of structure and possibly 
protein folding kinetics 
(76, 77) 
Fluorescence resonance 
energy transfer (FRET) 
Detection of coiled-coil formation, and 





hydrophobic interactions; while the uncharged urea does not interfere with charged 
residues and it is an overall indication for both electrostatic and hydrophobic interactions.   
 
1.2.4. Applications of coiled-coil motifs  
        Given the aforementioned attractive features of the coiled-coils, they are excellent 
models for protein engineering: the engineered coiled-coils have been translated into a 
wide variety of applications (25, 79). In the modern biopharmaceutical field, coiled-coil 
motifs are employed to fabricate novel biomedical devices, such as drug delivery systems 
(26), protein hydrogels (23, 27), new therapeutics, affinity purification and biosensors 
(80).  
        Two distinct research directions are a general focus and these are also the strategies 
adopted in this dissertation. First, coiled-coil motifs can be introduced as physical cross-
linkers to mediate sol-gel transitions upon corresponding environmental stimuli. In 1999, 
our group pioneered not only the concept but also the possibility of super-imposing the 
properties of peptides and synthetic polymers (22). Over 200 publications have been 
dedicated to this focus since then. Second, heterodimerization of coiled-coil motifs can be 
incorporated to develop pretargeted treatments for cancers (24, 26), such as 
radioimmunotherapy for lymphomas (81, 82). In this strategy, one strand of the coiled-
coil is attached onto the homing device (i.e., anti-tumor antibody or Fab’ fragment), and 
the other coil strand attached onto a therapeutic entity (e.g., drug or isotope). During the 
application, the first component is applied to pretarget/coat the target surface; then the 
second component is administered, “attracted” to the target surface due to the affinity 
biorecognition between the coiled-coil helices.    
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1.3. Physical Hydrogels 
        Hydrogels are polymeric materials that can absorb and retain substantial amount of 
water without breaking their three-dimensional scaffolds/networks (83, 84). Pioneering 
work from Wichterle and Lím proved the feasibility of using “hydrophilic gels” for 
biomedical use because of their unprecedented properties, such as low reactivity in 
biological environments and porosity for metabolites exchange/transportation (83). In 
1968, hydrogels became the first biomaterials for human use in the form of soft contact 
lenses (85). 
        Hydrogels can be categorized in several ways, such as synthetic (traditional), 
poly(amino acids)-based and hybrid hydrogels according to their composition; 
degradable and non-degradable hydrogels regarding their fate inside the body; covalent 
and physical hydrogels based on cross-linking mechanisms (84).  
        Covalent hydrogel networks can be acquired by bulk radical copolymerization of 
chain-forming monomers and suitable cross-linkers (86). For such purpose, typical 
monomers are mainly acrylate and methacrylate derivatives and so are the cross-linking 
agents, as listed in Table 1.2. Networks can be also built by cross-linking hydrophilic 
polymers (e.g., dextran, albumin and hyaluronic acid) derivatized with methacrylic acid 
(87). Other chemical cross-linking methods are also available, including reaction between 
complementary groups, and radiations induced and enzyme catalyzed cross-linking, as 
summarized by Hennink and colleagues (87). Interestingly, protein-based cross-linkers 
can be also used to build covalent hydrogels, such as engineered adenylate kinase (88). 
By adjusting the feed ratio of monomers/polymers and cross-linking agents, one can 
achieve desired cross-linking density,  degree of swelling,  mechanical strength,  porosity, 
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Table 1.2. Typical monomers and cross-linking agents for traditional hydrogel synthesis. 
Adapted from references (84, 97). 
 
Category Name 














and subsequently water content in the resulting hydrogels (83, 85). In comparison to free 
radical polymerization (89, 90), controlled/living polymerization (e.g., RAFT (91, 92) 
and ATRP (93, 94)) enable researchers to prepare (co)polymers with better defined 
molecular architecture. In addition, facile click-chemistry (95) is gaining ground in 
building precisely controlled copolymers and hence “click-gels” (96).   
        In contrast, physical hydrogel networks are interconnected via non-covalent 
interactions, which include molecular rcognition, ionic interactions, crystallization, 
hydrophilic and hydrophobic interactions, hydrogen bonds, and protein interactions (87). 
Therefore, the chemical issues of cross-linking agents involved in covalent hydrogels are 
avoided (87, 98). These hydrogels are oftentimes composed of different classes of 
building blocks with different mixed origins (natural vs. synthetic); if so, they can be also 
classified as hybrid hydrogels (99, 100). As illustrated in the following sections, self-
assembly of natural building blocks are commonly used as reversible cross-linking 
mechanism responding to various stimuli. Here physical hydrogels are reviewed in 
further details, with an emphasis on hybrid hydrogels containing protein/peptide 
components due to our research interest.   
 
1.3.1. Coiled-coil mediated physical hydrogels 
        Kopeček’s group pioneered research in physical hybrid hydrogels containing coiled-
coil folding motifs (22, 99). In 1999 (22), this group first empirically proved that self-
assembly of coiled-coil motifs into supercoils could be employed as physical cross-
linkers in hydrogel formation: two genetically engineered His-tagged coiled-coil motifs 
composed of a natural protein sequence (CC1, 255 amino acids, a.a.) and a de novo
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designed sequence (CC2, 72 a.a.), respectively, were chelated onto a hydrophilic N-(2-
hydroxypropyl)methacrylamide (HPMA, Figure 1.3) copolymer backbone via Ni2+ ions; 
these motifs self-assembled into tetramers and cross-linked the linear copolymer, forming 
physical gel networks. Moreover, swelling dynamics of resulting hydrogels shared 
temperature-responsiveness at similar transition temperatures of corresponding peptides; 
in other words, properties of the peptide component could be superimposed and 
integrated into the final hybrid materials. Further studies (101) showed that tailor-made 
stimuli-responsiveness of such hydrogels could be achieved by manipulating primary 
structure of these coiled-coil forming peptides, such as sequence (coiled-coil vs. noncoil-
coil domains), length (number of coiled-coil domains), etc. Physical hydrogels self-
assembled from di- and tri-block polypeptides containing coiled-coil peptide blocks were 
also developed by the same group, and gel swelling kinetics were successfully adjusted 
by proper arrangement of peptide blocks (59, 102). A common feature of these physical 
hydrogels is that peptides employed were generally long (>70 a.a.), and genetically 
engineered and biologically synthesized. 
        Enlightened by these successes, Kopeček’s group continued with the “next 
generation” coiled-coil mediated physical hydrogels, with the peptide component of 
significantly shorter sequence by chemical synthesis. Coiled-coil sequences containing 
only three to five heptads were designed and synthesized using solid-phase peptide 
synthesis, then grafted onto polyHPMA backbone through a polymer-analogue strategy; 
gelation studies revealed that coiled-coil forming peptides could be as short as four 




Figure 1.3. Hybrid hydrogel networks cross-linked by chelated coiled-coil motifs 
containing His-tags. Here the polymer backbone was poly(HPMA-co-DAMA) with 
pedant iminodiacetate groups for chelation with transition metal ions (e.g., Ni2+). Coiled-
coil forming peptides were attached with His-tags to chelate with the same metal ions. As 
shown, these motifs could form tetramers (one of the many possible confirmations) to 
physical cross-link the polymer backbones, resulting in hybrid hydrogel fromation. 
HPMA, N-(2-hydroxypropyl)methacrylamide; DAMA, N-(N’,N’-dicarboxymethylamino 




Similar to other coiled domains mentioned above, these short peptides self-associated 
into only homo-oligomers. To take one step further, a pair of complementary coiled-coil 
motifs (5 heptads in each), CCE and CCK, exclusively assembling into anti-parallel 
hetero-dimer, were designed and grafted onto polyHPMA backbone giving two 
complementary graft copolymers; upon mixing, two copolymers could reversibly self-
assemble into hydrogels at concentrations as low as 0.1 wt%, which demonstrated 
excellent recognition between the two peptides; more interestingly, this design allowed 
the possibility of in situ hydrogel formation since individual components were water 
soluble (104, 105). A general scheme of coiled-coil mediated physical hydrogels is 
shown in Figure 1.4a. 
        In this dissertation a continuous effort in building coiled-coil mediated physical 
hydrogels is described. Coiled-coil motifs of different lengths (3-5 heptads) were 
designed to form homooligomers as physical cross-linkers for gel formation. A new 
synthetic strategy, macromonomer copolymerization, was developed to prepare 
polyHPMA grafted with coiled-coil motifs; as possible influencing factors on gel 
formation, peptide sequences, copolymer concentration and environmental temperatures 
were scrutinized.  
        There are several intriguing features of coiled-coil mediate hybrid hydrogels in 
comparison to other monocomposition hydrogels. As pointed out above, the resulting 
hybrid constructs can possess unique properties by superimposing desired properties of 
both synthetic and peptide components (22), which allows these hybrid hydrogels to 
synergize the advantages of both traditional and protein-based hydrogels while 





Figure 1.4. Typical hybrid hydrogels: a) coiled-coil mediated self-assembly of hybrid 
hydrogels; b) β-sheet mediated self-assembly of hybrid hydrogels. 
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only to conventional stimuli (e.g., temperature and pH) but also biomolecules, minimized 
immunogenicity, improved biocompatibility, and even novel biofunctions. 
 
1.3.2. β-sheet mediated physical hydrogels 
        β-sheet is another commonly seen protein folding pattern and consequently a 
possible cross-linking mechanism for physical hydrogel construction (23, 107). Indeed, 
β-sheet forming polypeptide-based hydrogels have been well studied (108-110) for 
various applications, such as drug delivery and tissue engineering (107). As part of our 
research interest, hybrid hydrogels mediated by this folding pattern are briefly 
summarized here.  
        Stewart and colleagues (111) built a thermo-responsive hybrid hydrogel by using β-
sheet forming domain, titin immunoglobulin (Ig) module (I28, 111 a.a.), to cross-link 
linear polyacrylamide copolymers with the help of metal complex formation between 
nickel ions and pendant nitrilotriacetic acids (NTA); hydrogels obtained could experience 
an unusual positive swelling with elevated temperature (from 35 to 85 oC). Kopeček’s 
group (112) developed a diblock copolymer containing a β-sheet peptide (11 a.a.) 
segment and hydrophilic polyHPMA block that could self-assemble into fibrils; although 
the resulted architecture was not a hydrogel network, this study revealed the possibility of 
using short β-sheet peptides to construct self-assembling supermolecules and laid a 
foundation for further research in hybrid hydrogels. In addition, Tzokova et al. (113) 
found that a similar construct composed of poly(ethylene oxide) conjugated with β-sheet 
forming peptide (4 a.a.) could self-associate into soft hydrogels due to extra 
entanglements of the resulting β-sheet nanotubes. Indeed, a short while later Kopeček’s 
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group reported (114) the success of preparing hybrid hydrogels mediated by self-
association of β-sheet domains. In the design, a short peptide (Beta11, 11 a.a.) with 
strong propensity for β-sheet formation was designed and further randomly grafted onto 
polyHPMA backbone via polymer-analogue reactions; evaluation of resulting graft 
copolymers revealed that Beta 11’s β-sheet tendency was preserved and could cross-link 
polymer backbones leading to hydrogel formation, a process dependent on several factors 
(e.g., temperature, copolymer concentration and graft density). Currently, a similar 
approach is being explored to construct a hydrogel scaffold to facilitate template-directed 
biomineralization, based on the fact that acidic proteins in β-sheet conformation are 
involved in bone formation (115).  An example of hybrid construct containing β-sheet 
peptides was depicted in Figure 1.4b.  
        Other protein domains or peptide motifs have also been exploited regarding their 
incorporation into physical hydrogels. For example, calmodulin and elastin-like peptides 
were employed to develop reversible hydrogels, drug delivery systems and biosensors, as 
reviewed by Banta and colleagues (116).  
 
1.3.3. Other physical hydrogels 
        As a typical example of ionic interaction mediated hydrogels, negatively charged 
alginate at physiological pH can be cross-linked by Ca2+ ions and the resulting gels have 
been used for protein drug delivery and living cell encapsulation (98, 117). 
Stereocomplex formation can also mediate physical gelation as reported by Hennink’s 
group: hydrogels was prepared by mixing dextran grafted with D- and L-lactic acid (low 
molecular weight) oligomers in aqueous solution (118); bioactivity of an enzyme 
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(lysozyme) could be preserved after being released from such hydrogels (119). Physical 
hydrogels can also self-assemble from amphiphilic block and graft copolymers: for 
instance, poly(ethylene glycol)-block-poly(trimethylene carbonate) (PEG-b-PTMC) 
copolymer was developed as thermogelling material which could experience a sol-gel 
transition as temperature elevated, and transition temperatures could be manipulated by 
adjusting molecular weights of the blocks and polymer concentrations (120).  
        Biomolecular complexes, products of specific biorecognition between biomolecules, 
can also serve as reversible physical cross-linkers in hydrogel construction (121). Vinyl 
modified concanavalin A (Con A, a lectin binds glucose with a Kd≈10-6 M) was 
copolymerized with glucosyloxyethyl methacrylate (GEMA) resulting in a slightly cross-
linked interpenetrating network (IPN) with both chemical and physical (complex of Con 
A and glucose) cross-linkers, thus Con A was covalently immobilized in polymer 
network; in comparison to the physically entrapped Con A hydrogel network, the 
resulting hydrogels could experience reversible swelling in response to glucose and was a 
promising insulin delivery system in treatment of type I diabetes (122). To explore the 
reversible binding of antibody and antigen, vinyl derivatives of rabbit IgG and goat anti-
rabbit IgG were prepared and a semi-IPN composed of these two macromonomers was 
built using N,N’-methylenebisacrylamide (MBAA) as chemical cross-linker; results 
showed that the resultant hydrogels displayed swelling reversibility in concert with 
concentration change of free native rabbit IgG (123). Following a similar strategy, Con A 
and antibody were molecularly “imprinted” into a hydrogel network, which could 
specifically respond to α-fetoprotein (AFP), a tumor-specific glycoprotein; reversible 
formation of lectin-AFP-antibody complex in response to free AFP was the cross-linking 
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mechanism rendering reversibility of the resulting hydrogels, which can be used as a 
biosensor for diagnosis of hepatoma and cirrhosis (124).        
 
1.4. Affinity ligand pairs in pharmaceutics:  
pretargeted anticancer therapeutics 
and prodrugs 
        Conceived by Reardan et al. in 1985 (125), pretargeting strategy was developed to 
improve treatment efficiency of anticancer agents while minimizing their side effects 
(126-129). Focusing on anticancer applications, general principle for pretargeting is to 
specifically deliver the originally nonspecific effectors to tumors with the help of tumor-
specific moieties and even secondary helper molecules. Currently, there are two well-
studied directions following this strategy: pretargeted therapeutics/diagnostics and 
(pre)targeted prodrugs. In both scenarios, biorecognition between components (e.g., 
antigen-antibody and enzyme-substrate) plays a critical role leading to the final 
therapeutic effects. As a critical strategy adopted in this dissertation, pretargeted 
therapeutics are comprehensively reviewed in section 1.4.1 below. Targeted prodrugs, as 
an important concept and reference for our research, are briefly summarized in section 
1.4.2.  
 
1.4.1. Pretargeted anticancer therapeutics 
        The working philosophy for pretargeted anticancer therapeutics is to consecutively 
administer tumor-specific targeting moiety containing a recognition component 
(pretargeting agent), followed by a modified active therapeutic agent (effector) that can 
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directly or indirectly bind to that aforementioned recognition component; thus, effector is 
preferably accumulated specifically at tumor site leading to desired therapeutic effects, 
with unbound effector rapidly cleared out of the body to minimize undesired side effects 
(130). Therefore, pretargeting requires minimally two targeting components (131): a 
pretargeting agent to find tumor-specific target and to specifically bind to effector, and an 
effector to specifically interact with the former by specific affinity designs and 
subsequently to exert therapeutic effects. This dissociation of therapeutics from tumor 
targeting distinguishes pretargeting from conventional targeting. Since the concept of 
pretargeting initiated and intensively exploited in the area of readioimmunotherapy (RIT) 
and imaging, the following discussion is conducted within the same context. 
        There are three major systems widely explored to build pretargeted therapeutics 
(129): streptavidin-biotin (Figure 1.5), bispecific antibody-hapten (Figure 1.6) and 
oligomer-complementary oligomer (Figure 1.7). For each combination, distinct strategies 
have been developed according to its unique biological features. No matter which 
combination and strategy are employed, there are some general principles (132) to follow 
in the design so that unique advantages of pretargeting are ensured.  
        Successful effectors should possess the following chemical and physiologic 
properties (132). These chemical properties are low molecular weight (generally < 10 
kDa), hydrophilic to be compatible with biological environment, rapidly diffusible into 
extracellular fluid, negatively charged to avoid nonspecific binding, high-specificity 
toward the recognition component, and easy to be labeled with radionuclide. 
Physiologically, effectors should be cleared rapidly by kidney, with minimal organ 







Figure 1.5. Streptavidin-biotin pretargeting strategies. a) Two-step strategy with 
streptavidin-Ab (StAv-Ab) as pretargeting agent and radiolabeled biotin as effector. In 
between a chasing step can be added to remove free (StAv-Ab) from blood so that 
maximum degree of effector binding to tumor cells can be achieved. Here galactosylated-
biotin is shown as chasing agent. b) Three-step strategy with biotinylated-Ab as 
pretargeting agent, followed by chasing agent to remove free biotinylated-Ab from blood. 
Then streptavidin is injected to bind to localized biotins on cell surface, and finally 
radiolabeled biotin is administered. Here the chasing agent is avidin (a glycosylated 




Figure 1.6. Bispecific mAb-effector pretargeting strategy. Here a typical two-step scheme 
is shown, using bispecific mAb and divalent effector. Bispecific mAb can both 
specifically recognize tumor-specific antigen and metal-chelator (e.g., DOTA) or hapten 
peptide (e.g., HSG). If a fusion protein is used as bispecific pretargeting agent, it may 
exhibit a rapid clearance from blood due to its smaller size in comparison to 
corresponding chemical Fab’ X Fab’ conjugate. mAb, monoclonal antibody. Adapted 





Figure 1.7.	   MORF-cMORF pretargeting strategies. a) a conventional pretargeting with 
two steps, containing MORF-conjugated mAb and monovalent radiolabeled cMORF; b) 
pretargeting with affinity enhancement effect due to divalent radiolabeled cMORF; c) 
pretargeting with multivalent amplification effect from a system containing MORF-
conjugated mAb, polymeric cMORF, and monovalent radiolabeled MORF. MORF, 
phosphorodiamidate morpholino oligomer; cMORF, complementary MORF; mAb, 
monoclonal antibody. Adapted from reference (129). 
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low protein-binding. Preferred properties of primary targeting moieties have no major 
difference from those for directly conjugated antibodies; however, modern pretargeting 
prefers genetically engineered antibodies over the randomly conjugated ones via cemical 
modification due to their high specificity, low immunogenicity, and uniform structure 
(128, 133).   
        If these requirements are satisfied, pretargeted therapeutics can enjoy a superior 
advantage over their conventional counterparts (directly conjugated antibodies). 
Although directly radiolabeled monoclonal antibodies (mAbs) reach maximum tumor 
concentrations after 1-2 day, they circulate in the body for several more days, resulting in 
a low tumor/non-tumor (T/NT) ratio; consequently undesired damage to normal tissue 
results, especially to bone marrow. In pretargeting, “cold” pretargeting agents (modified 
mAbs) are not directly linked with radionuclides and their long-term presence does not 
induce toxicity; on the other hand, small radiolabeled effectors can find their pre-bound 
affinity targets within 1-3 h and nonlocalized ones are rapidly cleared from the body 
without accumulation. Therefore, pretargeting can achieve 2- to 3-fold enhancement of 
therapeutic agents over conventional targeting; if a chasing step is added to remove the 
free primary mAbs, the enhancement can be improved many fold (130). In turn, 
accumulation to liver, spleen and bone marrow is greatly reduced, so is the toxicity (132). 
Currently, pretargeted therapeutics are not perfect and limitations for different systems 




1.4.1.1. Streptavidin-biotin system 
        Ultra-high affinity  (Kd=10-13~10-15 M)  (134)  between streptavidin  (StAv,  60 kDa) 
and biotin (244.3 Da) makes them highly appropriate for pretargeting. Theoretically, both 
can be used as effectors; but the combination of radiolabeled StAv and biotinylated 
antibody (Ab) is not currently studied since the bulkiness of radiolabeled StAv leads to 
slow pharmacokinetics, violating the aforementioned design principles for effectors 
(132). Therefore, the commonly seen effector is radiolabeled biotin; but the primary 
targeting agent can be StAv-Ab or biotinylated-Ab. Different strategies have been 
developed corresponding to different arrangements: two- and three-step strategies (Figure 
1.5) (135). 
        In two-step strategy (Figure 1.5a), StAv is conjugated to tumor-specific mAb via 
chemical conjugation or genetic engineering, and the resulting pretargeting agent (StAv-
Ab) is first applied to bind tumor-specific antigen. Natural clearance of the unbound 
StAv-Ab can take up to several days due to their large sizes (~200 kDa) (131), thus a 
chasing step (usually 1-3 days afterward) is often adopted to remove the residual from 
blood prior to the injection of effector; otherwise, the majority of the radiolabeled biotin 
will be retained in circulation without reaching the tumor site. For instance, galactose-
coupled human serum albumin-biotin conjugate was designed for such a purpose: the 
albumin-biotin portion binds to StAv-Ab and blocks subsequent biotin binding; while the 
galatose portion serves for hepatocyte recognition so that the resulting complexes can be 
removed from blood and not compete for binding sites in the tumor (136). Increasing the 
pretargeting interval achieves the same effect of clearing pretargeting antibody, but at a 
possible cost of reduced antibody expression because of internalization (129). Finally, 
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“hot” biotin is administered, and localization of the effector to tumor and removal of the 
excess are obtained within a few hours, thanks to the rapid pharmacokinetics of effectors 
of small size (137).  
        In a three-step strategy (Figure 1.5b), the pretargeting agent is biotinylated-Ab 
binding first onto tumor cells. Later an intermediary step is employed: injection of avidin 
(Av, the glycosylated analogue of StAv) to remove excess pretargeting agent (chasing), 
followed by the administration of StAv to bind to localized biotin (bridging). After a 
suitable interval (~1 day) for the body to remove Av and StAv, radiolabeled-biotin is 
applied and localized localized in tumor, bridging by the tetravalent StAv.   
        Pretargeting based on StAv-biotin is mainly used for RIT and imaging. Karacay et 
al. (137) developed a two-step StAv-biotin system and tested its therapeutic efficiency in 
colorectal cancer. In their design, a chemical conjugation method was adopted to prepare 
the pretargeting agent – StAv-MN14 (an anti-carcinoembryonic antigen (CEA) mAb), 
with biotin-D-peptide-DOTA -111Indium (In) as effector and WI2 mAb (an anti-idiotype 
Ab) as chasing agent. In vivo results (138) demonstrated high tumor to blood ratio of the 
effector as 11:1 and 178:1 after 3 and 24 h, respectively; however, tumor accumulation of 
the effector via pretargeting was lower than the directly labeled Ab possibly due to the 
high concentration of endogenous biotin in mice and enhanced uptake of the effector by 
liver and kidney. 90Yttrium (139) was also chelated to biotin as effector and genetic 
engineering allowed for the production of StAv-mAb fusion protein (81, 140) as a new 
generation pretargeting agent. Some of these newer pretargeting modalities are in clinical 




        Overall,  these pretargeting  systems  did display  significant enhancement  of  T/NT 
ratio; however, this did not necessarily lead to high tumor retention of effectors (only 
~20%) because rapid pharmacokinetics of effectors resulted in fast clearance and left 
insufficient time for desired target binding (135, 138). This is actually a common issue 
for most pretargeting systems due to the unique design of effectors (131). Specific to 
StAv-biotin systems, the immunogenicity of StAv is another major limit for their future 
application (131).  
 
1.4.1.2. Bispecific antibody-hapten system 
        First proposed by Reardan (125), the other mode of pretargeting is to use bispecific 
Abs as pretargeting agents to localize radiolabeled effectors. A typical two-step scheme is 
illustrated in Figure 1.6: bispecific mAb is first administered and several days (1~7 days) 
are given to allow for binding and removal of excess mAb, where a chasing can be 
incorporated to facilitate the removal; then radiolabeled divalent effector is introduced, 
and tumor localization and residual removal are obtained within a few hours.              
        There are two ways to construct bispecific mAbs needed for pretargeting. A typical 
one (135) is chemical conjugation of Fab’ fragments of mAbs (Fab’ X Fab’), one against 
tumor-specific antigen and the other against effector, as first reported by Reardan et al. 
about 25 years ago (125). This method results in an architecture equivalent to F(ab’)2 
with a molecular weight around 100 kDa. Due to their bulkiness, removal of these 
bispecific mAbs from blood can take several days, before the injection of effectors (135). 
Fortunately, genetic engineering enabled researchers to prepare bispecific mAbs in a 
form of fusion proteins with uniform chemical structures, ease of manufacture, 
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dramatically smaller sizes and subsequently preferred clearing kinetics. Rossi et al. (142) 
produced two bispecific diabodies (~50 kDa) and two bispecific trivalent binding 
proteins (~80 kDa) using E. coli., and these fusion proteins can specifically bind with 
CEA and HSG (histamine-succinyl-glycine, a hapten peptide). Indeed, majority of the 
diabodies could be cleared out of blood within 8 h while preserving similar binding 
affinities toward targets as corresponding chemical Fab’ X Fab’, and tumor-to-blood ratio 
was improved more than 20 times. Using such bispecific mAbs, a chasing step is not 
needed any more. Additionally, fully humanized bispecific mAbs will be able to avoid 
immunogenicity (143), in comparison to the troublesome immunogenicity of StAv.  
        Besides tumor-specific antigen, bispecific mAbs need also to bind specifically to 
effectors. The exact effector target can be metal chelates (e.g., indium-
ethylenediaminetrtraacetic acid, In-EDTA) or hapten peptides (e.g., HSG). Targeting at 
chelates may restrict these bispecific mAbs to only certain chelate complexes (126), since 
the binding affinity between chealtor and corresponding antibody could be dramatically 
compromised by swapping radionuclides (e.g., from indium to gallium) (125). An 
alternative is to use peptide haptens that allow for specific recognition for certain mAbs 
and chemical modification, but are not directly responsible for chelation. Thus, a flexible 
and universal effector platform compatible with various radionuclides (e.g., 90Y, 111In, 
177Lu and 99mTc) can be built (143). 
        In contrast to the ultra-high affinity between StAv and biotin, binding between 
bispecific mAbs and haptens (or metal chelators) is weaker by 4-5 magnitudes (Kd≈10-9 
M). Therefore, effector valency is of great importance in determining tumor uptake and 
retention. Compared to monovalent effectors, divalent effectors can form more stable 
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complexes with bispecific mAbs, leading to higher tumor uptake (144, 145), known as 
affinity enhancement effect (129). Currently, the majority of the bispecific pretargeting 
systems employ divalent effectors, as show in Figure 1.6. In addition, multivalent 
bispecific mAbs (146) may further improve effector accumulation and T/NT ratio, as 
demonstrated by Rossi, et al. (147): a trivalent fusion protein (hBS14, ~80 kDa) was 
produced to contain two binding sites for CEA and one for HSG;  high  tumor  uptake  of  
effector (111In-bivalent HSG hapten, IMP-241), was observed and preferred T/NT ratio 
was achieved 3 h after injection.   
  
1.4.1.3. Oligomer-complementary oligomer system 
        To dodge possible immunogenicity of the former two pretargeting systems, a new 
dimension of pretargeting was formulated using complementary oligonucleotides and 
different oligomers were designed and tested for such purpose (148, 149). However, most 
of them were unsuccessful for different reasons, such as instability to nucleases, non-
specific binding to serum and proteins, and even insolubility in aqueous solution (150). In 
contrast, morpholino oligomers (MORFs) stood out with enhanced stability and 
acceptable water solubility (151), and became widely used for pretargeting. Different 
pretargeting strategies based on MORFs are summarized in Figure 1.7:  (a) conventional 
pretargeting with two steps, (b) pretargeting with affinity enhancement effect; (c) 
pretargeting with multivalent amplification effect.   
        In conventional two-step pretargeting (Figure 1.7a), MORF-conjugated mAb is 
prepared as pretargeting agent and applied first; after 2-3 days, radiolabeled cMORF is 
administered and localization can be measurably achieved around 3 h (150, 152-156). 
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This is the most intensively studied modality due to its simplicity. Similar to the 
bispecific mAb pretargeting system, radiolabeled divalent cMORF is proposed to further 
enhance tumor uptake (129), as depicted in Figure 1.7b. The third modality (Figure 1.7c), 
also called amplification targeting, is formulated based on a proof-of-concept studies 
from Hnatowich’s group (157, 158): after MORF-mAb, a polymeric cMORF construct 
containing multiple copies of cMORF is introduced as a intermediary bridging agent; 
then radiolabeled MORF is injected and subsequently radioactivity at tumor site should 
be amplified due to the multivalency effect. Research on the last two strategies is still on 
going. 
        In Chapter 3 and 4, we proposed a novel pretargeting system using specific 
biorecognition between a pair of complementary coiled-coil motifs to bridge Fab’ 
fragment and effector. Similar to the concept of amplification targeting, our effector was 
a polymeric construct containing multiple copies of coiled-coil motif, and the 
pretargeting agent was Fab’ fragment (anti-CD20 mAb) conjugated with one copy of the 
complementary motif. More importantly, our system contained neither radionuclide nor 
anticancer drug (30). 
 
1.4.1.4. Coordinating pretargeting agent and effector 
        In contrast to conventional targeting with direct linking of mAb and therapeutics, the 
biggest challenge for pretargeting is to coordinate the pretargeting agent and effector, 
mainly the interval between administrations and dosages. To do so, four variables need to 
be considered for typical two-step strategy: dosage of pretargeting agent, waiting duration 
prior to effector injection, dosage of effector, and waiting duration prior to 
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evaluation/detection. If chasing step is added or three-step strategy is employed, more 
factors will be involved for coordination. Currently, researchers are mainly relying on 
trial and error method to conduct optimization (129). Focusing on relatively simpler two-
step MORF system, Hnatowich’s group (129, 155, 156) proposed a semiempirical model 
trying to quantify the following factors: maximum percent and absolute tumor 
accumulation (MPTA and MATA) of effector, antibody accessibility and tumor 
saturation dosage of effector. This model can be an excellent reference for the 
optimization of our system described in Chapter 3 and 4, because of the similarity of the 
two.  
  
 1.4.2. Targeted prodrugs 
        Targeted prodrugs are designed to selectively deliver therapeutics to tumor site, so 
as to minimize side effects; in comparison, classical prodrugs aim to improve poor 
physicochemical properties (e.g., solubility and stability) of the active form (127). Both 
covalent and noncovalent linkage and active and passive targeting are employed in 
designing targeted prodrugs. Here, some typical examples are briefly discussed to 
demonstrate the current trends in targeted prodrug development; a comprehensive review 
can be found in reference (127).  
        The first example is a prodrug containing two components (carrier and targeting 
agent) that are noncovalently interacting with each other, with the cargo physically 
entrapped inside the carrier. Similar to pretargeted anticancer therapeutics, active 
targeting is employed. Gaidamakova and colleagues (128) developed a “molecular 
vehicle for target-mediated delivery of therapeutics” using a binary system: vascular 
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endothelial growth factor (VEGF) fused with a peptide (15 a.a.) as recognition tag, and a 
polyethyleneimine (PEI, DNA carrier) conjugated with a protein fragment (adapter) 
recognizing the tag. During the application, these two components were mixed first to 
form a complex (PEI-VEGF) via specific recognition between the tag and adapter; and 
cargo DNA was physically loaded onto the carrier beforehand. DNA in turn was 
selectively delivered to cells expressing VEGF receptors (VEGFR-2) on the surface. In 
vitro evaluation showed 3-15 times of VEGFR-2-mediated enhancement of luciferase 
(reporter protein) activity in VEGFR-2+ cells than in VEGFR-2- cells. In the design, 
authors successfully avoided chemical modification to targeting molecules so that such a 
platform (fused tag-conjugated adapter) could be universal for delivery of other cargos. 
Philosophically speaking, this system was equipped following pretargeting concept but 
delivered via conventional targeting fashion. 
        Another example falls in the category of antibody-directed enzyme prodrug therapy 
(ADEPT). Similar to typical pretargeting, ADEPT is a two-step strategy (159, 160). First 
a construct of tumor-specific mAb and prodrug-activating enzyme (conjugate or fusion 
protein) is applied and actively located in tumor; after the enzyme is cleared from 
circulation, an inactive prodrug (substrate of the enzyme) is systemically given and 
selectively activated at tumor site to kill cancerous cells. The enzyme should be 
exogenous or expressed at a low concentration to limit the release of active drug at non-
target; the prodrug should be a noncytotoxic substrate specific for that enzyme, and its 
active form should be small, diffusible and potent with bystander effect (127). Francis et 
al. (161) conducted a phase I clinical trial to examine the efficiency of an ADEPT on 
CEA expressing tumors. In their studies, a conjugate (A5CP) was constructed by linking 
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F(ab’)2 fragment of A5B7 (a mouse anti-CEA mAb) and CPG2 (a bacterial enzyme 
carboxypeptidase); and the prodrug employed was ZD2767P (bis-iodo phenol mustard). 
Results showed that 26 out of 27 patients responded to the therapy, and ZD2767P was 
cleared rapidly from blood and no active drug was detected in circulation; however, the 
enzyme conjugate was not sufficiently localized in tumor, and human anti-mouse and 
anti-carboxypeptidase antibodies were produced in response to the enzyme conjugate. 
Therefore, a chasing step may be needed to reduce the immunogenicity or a more 
efficient targeting agent must be designed. 
        Prodrugs can also passively target tumor, taking advantage of the leaky vasculature 
and impaired lymphatic drainage in tumor tissue, both of which allow macromolecules 
and nanoparticles to penetrate and accumulate in tumor, known as enhanced permeability 
and retention (EPR) effect proposed by Maeda and colleagues (162, 163). Kopeček and 
Duncan developed an HPMA copolymer conjugated with doxorubicin (DOX) via an 
enzyme-cleavable peptide linker (Gly-Phe-Leu-Gly, GFLG), and the final conjugate was 
designated as PK1 or FCE28068 (164). PK1 has a molecular weight of 28 kDa (DOX, 8.5 
wt%); GFLG is stable in plasma (165), but subject to intracellular cleavage by lysosomal 
cysteine proteinase (166) that releases DOX. During application, the prodrug is passively 
targeted and retained in tumor due to EPR effect, and further uptaken by tumor cells via 
pioncytosis. Subsequently, the conjugated DOX is liberated in lysosomal compartment 
upon cleavage. In phase I clinical trial, PK1 demonstrated antitumor effect with 
attenuated dose-limiting toxicity in comparison to intact DOX (163). This prodrug is now 




1.5. Cell death 
        Cell death plays a vital role in the development and homeostasis of organisms. There 
are two major types of mammalian cell death according to the widely used classification: 
apoptosis and necrosis (168). However, recently discovered autophagy and cornification 
are considered as the third and fourth types of cell death. According to the definition of 
programmed cell death, apoptosis, autophagy and cornification are genetically controlled. 
Additionally, there are some atypical cell death modalities, including mitotic catastrophe, 
anoikis, excitotoxicity, Wallerian degeneration, pyroptosis, paraptosis, pyronecrosis, and 
entosis (169). Cross-talk among different mechanisms are commonly seen. For instance, 
necrosis can be initiated or controlled by the programmed mechanisms under certain 
circumstances (170). Accumulating knowledge about cell death has greatly facilitated the 
development of new therapeutic strategies for diseases.  
 
1.5.1. Apoptosis 
        Apoptosis (“leaves falling from trees”) was coined by Kerr et al. (171) to describe a 
specific series of morphological changes during cell death (Table 1.3). It is a form of 
programmed cell death, but not a synonym of programmed cell death.  
        Opposite to the effect of pleomorphoic adenoma gene producg (PLAG) (172), 
activation of caspases sentences cells to one of the two distinct but convergent pathways: 
death-receptor (extrinsic) and mitochondrial (intrinsic) apoptotic pathways (173). Death-
receptor pathway involves the binding of death ligand (e.g., tumor necrosis factor (TNF)) 
to death receptor, subsequent formation of death-inducing signaling complex (DISC) and 
the activation of caspase 8,  a central initiator of apoptosis. Activated caspase 8 can either 
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Table 1.3. Different cell death modalities. Adapted from Reference (169).  
Cell death modality Morphological features 
Apoptosis Cell rounding-up 
Pseudopods retraction 
Cell and nucleus shrinkage (pyknosis) 
Nuclear fragmentation (karyorrhexis) 
Cytoplasmic organelles modification 
Plasma-membrane blebbing 
Engulfment by phagocytes 
Autophagy Absence of chromatin condensation 
Sequestration of cytoplasmic materials  
Formation and accumulation of double-membraned autophagosomes 
Little or no association with phagocytes 
Necrosis Cell and organelle swelling (oncosis) 
Rupture of surface membranes 
Spillage of cell contents  




directly activate caspase 3 (executor of apoptosis) or be detoured to mitochondrial 
pathway. In mitochondrial pathway, caspase 8 or intracellular stress induces the release 
of cytochrome c, which in turn activates caspase 9 (another initiator of apoptosis) through 
apoptosome. Activated caspase 8 and 9 share the same duty: activating caspase 3. Bcl-2 
family proteins are the gatekeepers for apoptosis and they can be either death antagonists 
(e.g., Bcl-2 and Bcl-w) or agonists (e.g., Bax, Bak and Bad) (174).  
        Apoptosis is the most thoroughly studied cell death mechanism and there is a 
collection of tools to qualify and quantify apoptosis. Microscopy is frequently used to 
visualize the morphological features of apoptotic cells and flow cytometry (e.g. 
fluorescence-activated cell sorting, FACS) is intensively used to quantify apoptosis (169). 
Facilitated by flow cytometers, several standardized analysis methods were developed: 
caspase 3 activity assay (175), terminal transferase dUTP nick end labeling (TUNEL) 
assay (176, 177), and Annexin V/propidium iodide (PI) staining (178, 179).  
   
1.5.2. Autophagy  
        Autophagy (“to eat oneself”) is a closely regulated lysosomal self-digestion process 
in which cells recycle and consume their own nonessential, redundant or damaged 
organelles and macromolecular components (168, 180). Corresponding morphological 
features of autophagy are delineated in Table 1.3. Initially as a pro-survival pathway, 
autophagy can steer cells through nutrient deprivation or damages; but if the stress or 
damage is too severe to overcome, cells may die through apoptosis (180). This a typical 
example of cross-talk between autophagy and apoptosis, which are acting in concert and 




        Necrosis (necroptosis) is manifested in cell and organelle swelling (oncosis), and 
rupture of plasma membrane and subsequent spilling of intracellular contents (168, 169). 
Key features of necrosis are also listed in Table 1.3. Although considered as uncontrolled 
accidental form of cell death for a long time, growing evidence is suggesting that necrosis 
is also fine-tuned by some transduction pathways and catabolic mechanisms (182). In 
contrast to apoptosis and autophagy, necrosis typically associated with inflammation 
caused by the spillage of cell contents.      
 
1.5.4. Medical implications of apoptosis 
        The best-characterized apoptotic machinery has been revealed to play a critical role 
in many diseases, such as cancer, autoimmune disease, neurological disease, hepatitis, 
cardiovascular disease and sepsis (168). In combating these diseases, two major strategies 
to modulate dysregulated apoptosis have been developed: induction and inhibition. For 
instance, Gleevec® was marketed to induce apoptosis by inhibiting tyrosine kinase to 
treat leukemia (183), and Hycamtin® (topotecan) induces apoptosis by inhibiting 
topoisomerase I in ovarian cancer (184, 185). Cyclosporine is being used to inhibit 
apoptosis in myocardial infarction by inhibiting mitochondrial permeability transition 







1.6. Non-Hodgkin’s lymphoma (NHL)  
1.6.1. NHL overview        
        Non-Hodgkin’s lymphoma  (NHL) is a large group of lymphocyte (white blood cell) 
cancers, and it is one (6th, projected in 2010 (187)) of the top ten cancers in the United 
States. NHL can occur to both sexes at any age and the age-adjusted incidence rate was 
19.6 per 100,000 per year in 2007 (188); and the projections for 2010 are 65,540 and 
20,210 for new cases and deaths from NHL, respectively (187). Common symptoms of 
NHL may include fever, unexplained weight loss, fatigue and larger than normal lymph 
nodes. 
        Classification of NHL is of great importance for reproducible diagnosis and 
subsequent treatments. Experiencing many classification systems and revisions, the 
current WHO classification (Table 1.4) has become a worldwide standard for clinicians 
and researchers (189,190). This classification is mainly based on immunological features, 
genetic alterations and clinical characteristics of the disorders. In the United States, B-cell 
lymphoma, making up over 85% of NHL incidences, is much more common than its T-
cell counterpart.  
 
1.6.2. NHL treatments 
        NHL pathogenesis, phenotype and stage altogether determine the selection of 
therapeutic regimens. The treatments currently available and in clinical trials can be 
roughly categorized as: local surgery (191), chemotherapy (192), radiotherapy/RIT (193), 




Table 1.4. Different types of non-Hodgkin’s lymphoma (NHL). Summarized from 
references (189, 190). 
 
Category Name 
Precursor B-cell lymphoblastic lymphoma 
Follicular lymphoma (FL) 
Mantel cell lymphoma (MCL) 
Small lymphocytic lymphoma (SLL)/ 
Chronic lymphocytic leukemia (CLL) 
Marginal zone B-cell lymphoma (MZL) 
Extranodal marginal zone lymphoma of mucosa-associate 
lymphoid tissue (Extranodal MZL of MALT) 
Splenic marginal zone lymphoma (SMZL) 
Nodal marginal zone lymphoma (NMZL) 
Lymphoplasmacytic lymphoma (LPL) 
Diffuse large B-cell lymphoma (DLBCL) 
Lymphoid tumors of 
B-cell lineage 
Burkitt’s lymphoma (BL) 
Precursor T-lymphoblastic lymphoma/leukemia 
T-cell prolymphocytic leukemia (T-PLL) 
T-cell large granular lymphocytic leukemia (T-LGL) 
Aggressive natural killer-cell leukemia 
Adult T-cell leukemia/lymphoma 
Mycosis fungoides (MF) 






vaccines) (195). The combinations of these treatment modalities are frequently used to 
achieve better therapeutic outcomes.  
        Drug conjugates, especially polymeric drug conjugates, are promising in treating 
NHL.  Polymeric  modification  can give a  “facelift”  for the anticancer  agents with 
poorproperties. Such kind of improvement may include: 1) enhanced stability, 2) 
improved solubility, and 3) increased therapeutic effect with reduced side effects due to 
the EPR effect. Conjugation of L-asparaginase to PEG led to Oncaspar ®, which was 
approved by FDA in 1994 for NHL treatment; clinical trial results revealed that the 
enzyme’s plasma half-life was extended from ~20 h (native) to ~360 h (conjugate) (196), 
and pegylation indeed greatly decreased toxicity and hypersensitivity reactions (197). 
Another well-studied anti-NHL drug conjugate is cyclodextrin-based polymer conjugate 
of camptothecin (IT-101): the native camptothecin (CPT) has poor solubility, and 
consequently high toxicity and low therapeutic efficacy; after conjugation to 
cyclodextrin, CPT’s plasma half-life was prolonged from 1.3 to 17-20 h, preferential 
accumulation of the conjugate at tumor site was observed, and extended release of CPT 
from the conjugate was also achieved (198, 199).  
        Recently, monoclonal antibody-drug conjugates (ADCs) have caused great attention 
and are considered as a new direction for fighting NHL (200). A cohort of surface 
antigens for B-cell NHL has been identified: CD19, CD20, CD21, CD22, CD23, CD40, 
CD52 and CD80. Corresponding mAbs have been identified and explored for NHL 
treatment. Based on these antibodies, various ADCs have been developed and some are 
already in clinical trials. For example, calicheamicin was attached to inotuzumab 
targeting CD22, and the conjugate is now in phase I/II clinical trials; auristatin was 
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conjugated to brentuximab guiding the final ADC (SGN-35) to CD30 (194). CD20-based 
ADCs will be discussed with further details in section 1.7.   
  
1.6.3. Animal models for NHL study      
        Due to the prevalence of NHL, researchers have spent great effort finding an 
effective cure. Different animal models have been developed to simulate human NHL. 
Mice models are currently the best-established models to test different treatment 
modalities. This is mainly due to their low cost, ease of manipulation, and more 
importantly their surprisingly genetic similarity to human.  
        Currently two type of NHL mice models are in use: local solid tumor and systemic 
tumor models. Both models can be easily generated via s.c. and i.v. injection of 
lymphatic cells, respectively. The commonly used cell lines include Raji, Daudi, Ramos, 
Namalwa, Karpas 299 and L540 (199, 201). In comparison, i.v. inoculation leads to a 
natural NHL model, a closer simulation of NHL in human body (non-localized and 
disseminated) (202).    
        Two major strains of mice are commonly used in NHL study: athymic nude mice 
and severe combined immunodeficiency (SCID) mice. Athymic nude mice are mainly 
used to generate localized NHL tumor models after s.c. injection of tumor cells; the 
subsequent tumor size monitoring and tumor harvest are easy to be performed on these 
nude mice due to the absence of thick body hair (199, 203). SCID mice, deficient in T- 
and B-cell functions, are generally considered permissive/tolerant for human tumor 
xenograft without rejection. Nonobese diabetic (NOD) (204, 205) and C.B-17 SCID 
(206-208) mice are two commonly seen strains used to construct systemic NHL models, 
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and they are developed to overcome the leakiness of the SCID mutation and the non-
lymphoid specific mutation (209). NOD SCID mice have all T, B and natural killer (NK) 
cell activities deficient; while C.B-17 SCID mice preserve the normal NK cell activity, 
which was reported to be helpful for the depletion of disease B cells upon treatment 
(202). Therefore, C.B-17 SCID mice are a better choice at least for NHL studies and were 
employed in our in vivo experiments.   
 
1.7. CD20 surface antigen 
1.7.1. CD20 biology 
        CD20 is a nonglycosylated phosphoprotein of 33-37 kDa with four transmembrane 
domains, belonging to a membrane-spanning four-domains subfamily A (MS4A) (210, 
211). Its expression is restricted to the surface of nearly all (>95%) committed (normal 
and malignant) B-cells, and dramatically downregulated at the point of differentiation 
into plasma cells (212, 213). However, it is not expressed on uncommitted hematopoietic 
progenitor stem cells (213) and plasma cells (214), which implies that the normal B-cell 
homeostasis can be reestablished after treatment. In addition, CD20 is noninternalizing, 
nonshedding and noncirculating (215). Thus it is considered as one of the most reliable 
phenotypic biomarkers for B-cell NHL and a very useful target for treating the same 
disease (216-218). 
        CD20 can homo-oligomerize into dimer and tetramer (219, 220). It is a substrate of 
and closely associated with tyrosine and serine kinases (221, 222). It is also proved to be 
constitutively associated with lipid rafts in the cell membrane (217, 223-225). Although 
there is no direct evidence of CD20 forming an ion channel, it has been strongly 
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suggested that CD20 is somehow intimately linked to store-operated calcium entry 
(SOCE) channels (219, 226-228). These distinct structural features are believed to be 
related with the postulated functions of CD20 (229): B-cell activation, proliferation and 
differentiation (230, 231); membrane calcium conductance (228); and induction and 
regulation of apoptosis (217, 232).   
 
1.7.2. Anti-CD20 antibodies 
        CD20 spans through B-cell membrane four times and hence presents a single 
extracellular loop of ~43 residues between the third and fourth transmembrane domains, 
providing epitopes for the binding of various antibodies (215, 233). However, there is a 
high degree of epitope variation among the antibodies, despite the small size of this loop. 
This may imply different potencies and consequences of the antibodies upon binding to 
CD20 (234).   
        Due to the intriguing features of CD20 and proven value as a drug target, anti-CD20 
mAbs of different origins (Table 1.5) have been identified, engineered and tested for the 
treatment of B-cell NHL. Based on the epitope and/or binding mode, these antibodies are 
divided into type I and II. Type I mAbs stabilize CD20 on lipid rafts, resulting in stronger 
C1q binding and complement-dependent cytotoxicity (CDC) induction. In contrast, type 
II mAbs do not stabilize CD20 but potently induce direct cell death (apoptosis) (235). 
Type I is more commonly seen than type II. New mAbs are engineered for better 
therapeutic potency over the first generation rituximab: second generation is humanized 
or fully human antibodies without alteration to Fc region, and third generation is both 
humanized and  Fc-region reengineered  (236) . The rationale  behind  this  evolution is to  
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 Table 1.5. Various anti-CD20 monoclonal antibodies (mAbs) 




Up-regulates c-myc expression; 






Induces homotypic aggregation. 
(217, 234) 




Chimeric: binding region of murine 
anti-human CD20 + hIgG1 heavy-
chain + human κ constant region; 
Approved by FDA in 1997. 
(218) 
Y90-ibritumomab 
tiuxetan (type I) 
 
aka, Zevalin® from Biogen IDEC; 
Radioconjugate murine mAb; 




aka, Bexxar® from GSK; 
radioconjugate with murine B1 mAb; 




Aka, IMMU-106, hA20; 
>90% humanized framework; 




Fully humanized IgG1; 






Fully human IgG1; 




1st Fc-engineered type II humanized 
IgG1; 
50-fold higher binding affinity; 
10 to 100-fold increase in ADCC and 















m, murine; h, human. 
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minimize infusion reactions and to diminish the development of human antibodies 
against the therapeutics (237).     
 
1.7.3. Anti-CD20 antibody-based treatments for NHL 
        At present, there are two major therapeutic modalities based on anti-CD20 
antibodies available in clinical use: 1) bio-/immuno-therapy directly using unconjugated 
anti-CD20 mAbs, and 2) radio-immunotherapy using anti-CD20 antibody conjugates. In 
1997, Rituximab (Biogen IDEC) became the first therapeutic mAb approved by US FDA 
(247). Since the exact functions of CD20 are unclear, there are only some postulated 
mechanisms of action of rituximab, as illustrated in Figure 1.8: complement-dependent 
cytotoxicity (CDC), antibody-dependent cellular toxicity (ADCC) and direct induction of 
apoptosis (215, 235). Now rituximab is the first-line monotherapy for follicular 
lymphoma, and is also used in combination with chemotherapy for indolent, intermediate 
and aggressive NHLs. However, rituximab is not perfect; it is accompanied by mild to 
serious side effects, such as fever, chill, hypotension, infusion reactions, tumor lysis 
syndrome (TLS), severe mucocutaneous reactions, progressive multifocal 
leukoencephalopathy (PML) (www.rituxan.com) (215). PML is a rare and life-
threatening brain disease caused by human polyomavirus John Cunningham virus (JCV), 
which causes myelin loss upon infection (248). Recent studies indicated that the 
depletion of peripheral B cells after rituximab treatment motivates the release of 
heomatpoietic progenitor cells from bone marrow, which creates a favorable scenario for 
JCV migration and proliferation (249). The mounting number of PML adverse event 








rituximab has been observed (218). Accumulating evidence is suggesting that 
polymorphism of Fcγ receptors in ADCC (218, 251) and the complement activation in 
CDC (252) contribute greatly to the resulting drug resistance and side effects. 
        The early success of rituximab heralded a new era in novel NHL treatment 
approaches. Radio-immunotherapy (RIT) for NHL treatment is an excellent example: 
conjugating radioisotopes with anti-CD20 antibodies to improve treatment efficacy while 
limiting toxic effects on normal cells. In February 2002, Yttrium-90 (90Y)-ibritumomab 
tiuxetan (Zevalin® Biogen IDEC) was approved by FDA, the first FDA approved RIT 
conjugate. In June 2003, FDA approved another RIT conjugate, iodine-131 (131I)-
tositumomab (Bexxar®, GlaxoSmithKline), for the treatment of CD-20 positive follicular 
NHL. Both of them achieved satisfying therapeutic effect in patients, gauged by the 
response rate (RR) and complete remission (CR) rate (216). Currently, the combination 
of RIT with other chemotherapeutic agents are in clinical trials (237).  
        CD20-based antibody-drug conjugates (ADCs) have also been developed to improve 
therapeutic efficiency of the native anticancer agents. For instance, the aforementioned 
auristatin was “glued” onto rituximab and 1F5 antibodies via a lysosomally cleavable 
dipeptide (valine-citrulline) linker; results from in vitro and in vivo studies both indicated 
the ADCs could achieve better therapeutic effects than rituximab alone (253).  
        Cross-linking of CD20 antigens is believed to trigger certain signaling pathway and 
further to result in direct apoptosis during the rituximab treatment (217). Back in 2001, 
Ghetie and colleagues (201) already proposed that the homodimers but not monomers of 
rituximab induced the apoptosis in NHL. Supposedly, secondary antibodies should be a 
straightforward strategy to cross-link the primary anti-CD20 mAbs (217). Following this 
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thread, Zhang et al. (202) generated a rituximab-dextrin polymer conjugate and their 
results proved that the hyper-cross-linking of CD20 antigens did lead to a clinically 
relevant level of apoptosis due to the multivalency effect of the conjugate; a goat anti-
human secondary antibody was employed to cross-link rituximab as a positive control in 
this study.  
        To minimize the infusion reactions and other severe side effects of murine and 
chimeric antibody-based therapeutics, highly and fully humanized anti-CD20 antibodies 
have been developed and some are already in clinical trials (241), as listed in Table 1.5. 
For example, a >90% humanized mAb, IMMU-106, was tested in a phase I/II dose-
escalation study. Encouraging preliminary results in patients showed an overall RR of 
53% and a CR rate of 40%, with a short infusion time and reduced infusion reactions 
compared to rituximab (237).   
 
1.8.  Statement of objectives 
        The objective of this dissertation was to study the biorecognition of coiled-coil 
sequences in both hybrid biomaterials and macromolecular therapeutics, designed with 
affinity coiled-coil interactions: in particular, to determine the factors responsible for the 
coiled-coil mediated self-assembly of graft copolymers into hybrid hydrogels and to 
apply the biorecognition principles to a biological system. To this end, two major specific 
aims were formulated: 
1) To synthesize HPMA copolymers grafted with coiled-coil forming peptides and to 
evaluate the relationship between peptide/graft copolymer structure and the self-
assembly into hybrid hydrogels. 
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2) To design a system where coiled-coil biorecognition would mediate a biological 
process, apoptosis induction in CD20 positive B cells, to prove that coiled-coil 
formation at the cell surface could cross-link CD20 antigens and trigger apoptosis, and 
to further evaluate this system both in vitro and in vivo.  
        To accomplish these specific aims, self-assembly of coiled-coil motifs was 
employed as a core element in the design to mediate either gel formation or multivalent 
cross-linking events on B cell surface. In Specific Aim 1, we proposed a free radical 
macromonomer copolymerization strategy to synthesize polyHPMA copolymers grafted 
with coiled-coil motifs, whose self-assembly would in turn function as a cross-linking 
mechanism for novel hybrid hydrogel formation; moreover, we would like to examine the 
impact of sequence design and micro-environment on gel formation. These results are 
described in Chapter 2. In Specific Aim 2, the unique molecular biorecognition between 
two self-complementary coiled-coil motifs (CCE and CCK) was used to mediate the 
cross-linking of CD20 surface antigens, which could trigger respective signaling cascades 
and concomitantly induce apoptosis of the malignant B cells. These results are described 
in Chapters 3 and 4. 
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CHAPTER 2 
 
NOVEL SYNTHESIS OF HPMA COPOLYMERS CONTAINING  
PEPTIDE GRAFTS AND THEIR SELF-ASSEMBLY 
 INTO HYBRID HYDROGELS 
 
2.1. Summary 
         A new pathway for the synthesis of N-(2-hydroxypropyl)methacrylamide (HPMA) 
copolymers containing coiled-coil forming motifs of different sequences was developed 
and their self-assembly into hybrid hydrogels was investigated. Linear water-soluble 
polyHPMA was chosen as the polymer backbone due to its excellent biocompatibility. 
Upon macromonomer copolymerization, coiled-coil motifs were covalently attached onto 
the polymeric backbone forming the grafts. Peptide chain length was one of the major 
factors examined in this study regarding its influence on gelation ability of the resulted 
graft copolymers. Results showed that at least four heptads were needed to facilitate the 
hybrid system to form hydrogels under the experimental conditions tested. Other possible  
________________________________________________________________________ 
Note: This chapter is reprinted with permission from the following publication: Wu, K., 
Yang, J., Koňák, Č., Kopečková, P., and Kopeček, J. (2008) Novel synthesis of HPMA 
copolymers containing peptide grafts and their self-assembly into hybrid hydrogels. 
Macromol Chem Phys 209, 467-475. 
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factors affecting the kinetics of hydrogel self-assembly were also scrutinized: 
concentration and temperature. These factors played a critical role in the process of self-
assembly and gel formation, as demonstrated in this study. 
 
2.2. Introduction 
        Hybrid hydrogels are usually referred to as hydrogel systems with components from 
at least two distinct classes of molecules, for example, synthetic polymers and biological 
macromolecules, interconnected either covalently or noncovalently (1, 2). Peptide and/or 
protein segments have been used to introduce degradability (3-5), temperature-dependent 
phase responsiveness (6, 7) and sensitivity to the presence of active biomolecules (8, 9) 
into the hybrid hydrogel structure. Water-soluble synthetic polymers have been cross-
linked with molecules of biological origin, such as oligopeptides (3-5), oligodeoxyribo-
nucleotides (10), cross-linking agents containing oligolactate esters or oligoglycolate 
esters (11), stereospecific D,L-lactic acid oligomers (12) or antigen-antibody binding (8).  
        Numerous protein motifs have been combined with synthetic polymers to produce 
macromolecules whose self-assembly into hydrogels is mediated by protein domains (6, 
13-18). One of the frequently used protein folding motifs is the coiled-coil. It consists of 
two or more α-helices wound together forming a super-helix (19). Its primary structure is 
featured by repeats of heptad, seven amino acid sequence designated as (abcdefg)n, where 
a and d positions are usually taken by hydrophobic residues. The formation and stability 
of coiled-coils depend on the structure and the number of heptad repeats (20). The 
distinctive feature of coiled-coils is the specific spatial recognition, association and 
dissociation of the helices, making it an ideal model for protein biomaterials in which the 
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higher structure may be pre-determined by the primary amino acid sequence (21, 22). 
        Recently, N-(2-hydroxypropyl)methacrylamide (HPMA) graft copolymers contain-
ing coiled-coil sequences were designed and their self-assembly into hydrogels evaluated 
(13, 14). One of the designs was composed of a linear, water-soluble polyHPMA as 
polymer backbone, and coiled-coil forming peptides as grafts. Three peptides of different 
chain lengths [(VSKLESK)n-(KSKLESK)-(VSKLESK)GYC, n=1-3] were attached to an 
HPMA copolymer precursor by a polymer-analogous reaction of SH groups with male-
imido groups at the termini of the copolymer side chains (13). The results revealed that 
the length and number of coiled-coil grafts per macromolecule had a significant impact 
on the gelation process. 
        Alternatively, peptide grafts can be incorporated into water-soluble polymers by 
radical copolymerization of a peptide-containing macromonomer and a primary chain-
forming monomer, such as HPMA or acrylamide. For instance, synthetic peptide 
vaccines were prepared by copolymerization of acrylamide with peptides capped at the 
N-terminus with N-acryloylaminohexanoyl groups (23). Targetable HPMA copolymer-
photosensitizer conjugates were prepared, in a one-step process, by copolymerization of 
HPMA, a polymerizable derivative of mesochlorin e6 (photosensitizer) and a polymeri-
zable Fab’ antibody fragment (24). 
        Here, three macromonomers, containing coiled-coil forming peptides of the 
structure [(VSKLESK)n-(KSKLESK)-(VSKLESK), n=1-3], and capped at the N-
terminus with an N-methacryloylglycylglycyltryptophan spacer, were synthesized by 
solid phase peptide synthesis and copolymerized with HPMA. The influence of graft 
length, concentration and temperature on the self-assembly of graft copolymers into 
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hydrogels was evaluated by physicochemical methods, including circular dichroism (CD) 
spectroscopy, microrheology and dynamic light scattering (DLS). 
 
2.3. Materials and methods 
2.3.1. Materials 
        Side-chain protected Fmoc-amino acids, 2-chlorotrityl resin, 1-hydroxy-benzo-
triazole (HOBt), and benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluoro-
phosphate (PyBOP) were purchased from Novabiochem (San Diego, CA). N,N-dimethyl-
formamide (DMSO) was purchased from EMD Chemicals, Inc. (Gibbstown, NJ). 2,2,2-
trifluorothanol (TFE), DMF, trifluoroacetic acid (TFA), methanol and piperidine were 
purchased from VWR International (West Chester, PA). HPMA (25) and N-methyacryl-
oylglyglycine (MaGG-OH) (26) were synthesized as previously reported. The water-
soluble azo-initiator, VA044, was obtained from Wako Chemicals (Richmond, VA). 
 
2.3.2. Macromonomer synthesis and purification 
        Macromonomers containing 24, 31 and 38 amino acids (Table 2.1) were synthesized 
using a solid phase method and a manual Fmoc/tBu strategy on 2-chlorotrityl resin, as 
described previously (13, 27). The peptides contained 3, 4 and 5 coiled-coil forming 
heptads (Figure 2.1) and N-termini capped with a N-methacryloylglycylglycyltryptophan 
spacer. A fragment condensation strategy was adopted. After the attachment of 14 amino 
acid residues, corresponding number of side-chain protected VSKLESK segments were 
coupled. Finally, peptides were cleaved and side-chains deprotected from the resin using 
a TFA/H2O/triisopropylsilane (95:2.5:2.5)mixture for 2 h under constant shaking.  
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# of amino 
acids Theoretical Measureda) 
MaCC3b) Ma-GGW(VSLKESK)1  
KSKLESKVSKLESK 
24 2731.2 2731.6 
MaCC4 Ma-GGW(VSLKESK)2 
KSKLESKVSKLESK 
31 2504.0 2504.1 
MaCC5 Ma-GGW(VSLKESK)3 
KSKLESKVSKLESK 
38 4275.4 4275.6 
a) molecular weight measured using MALDI-TOF MS; b) Ma, methacryloyl; CC, coiled-
coil; 3 (4 or 5), number of heptads. 
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Figure 2.1. Schemes for macromonomers synthesis, free radical copolymerization, and 
self-assembly of the graft copolymers into hybrid hydrogels.  
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Crude macromonomers were purified using RP-HPLC (Agilent Technologies, Zorbax 
300SB-CN, 9.4×250 mm, 5 µm, flow rate of 3 mLmin-1) with a gradient from 20 to 40% 
of buffer B within 40 min. Buffer A was 0.1% TFA in water and buffer B 0.1% TFA in 
acetonitrile.  Yields of macromonomers were 5–15%. Macromonomer structures were 
validated using matrix-assisted laser desorption-ionization time-of-flight mass 
spectroscopy (MALDI-TOF MS) (Voyager-DE STR Biospectrometry Workstation, 
Perseptive Biosystems). 
 
2.3.3. Graft copolymer synthesis and purification 
        HPMA and corresponding macromonomers were copolymerized by free radical 
copolymerization (Figure 2.1) in water using VA044 as the initiator. For example, 
HPMA (2.86 mg, 2×10-5 mol) and MaCC3 (2.87 mg, 10-6 mol) were mixed in an 
Eppendorf tube and purged with N2 for at least 10 min; then 23 µL VA044 (0.206 mg, 
6.4×10-7 mol) aqueous solution, prebubbled with N2 for 5 min, was added to dissolve the 
particles. The reaction solution was transferred and sealed in a capillary tube, and main-
tained at 50 oC for 20 h. Crude graft copolymers were collected by precipitation into an 
excess of acetone and further purified by size exclusion chromatography (SEC) (ÄKTA, 
Amersham Pharmacia Biotech; Superose 12 column) using phosphate-buffered saline 
(PBS, pH=7.4) as mobile phase. Fractions containing target copolymers were pooled, 
dialyzed against distilled water to remove salts and then freeze-dried. Final yields of 
copolymers were 40–60%. The molecular weight and molecular weight distribution of 
the copolymers were measured by SEC using ÄKTA system equipped with ultraviolet 
(UV) and refractive index (RI) detectors on a Superose 6 HR10/30 column eluted with 
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PBS (pH=7.4). The average molecular weights were calculated against a calibration with 
polyHPMA fractions. Graft contents in copolymers were determined by UV spectro-
photometry (tryptophan: ε=5,580 Lmol-1cm-1 at 280 nm in PBS) (28, 29). Key features 
of the graft copolymers are summarized in Table 2.2. 
 
2.3.4. Circular dichroism (CD) spectroscopy 
        Circular dichroism (CD) spectra were collected on an Aviv 62DS CD spectrometer 
with a thermoelectric temperature control system. All samples were dissolved and 
dialyzed against benign buffer (5×10-2 M Na2HPO4/NaH2PO4/0.1 M KCl, pH=7.0) for 6 
h using a dialysis membrane with a molecular weight cut-off of 2 kDa. Final 
concentrations of the peptides were determined by UV spectroscopy at 280 nm (≈10-4 M). 
Wavelength scans were recorded at a step-width of 1 nm with a 5 sec averaging time at 
each step from 200 to 250 nm using a 0.1 cm path length quartz cuvette. The spectra 
acquired were averaged from three consecutive scans and subtracted from the 
background. Ellipticity was reported as the mean residue ellipticity ([θ], in degcm2dmol-
1) calculated using function 2.1: 
€ 
θ[ ]222 = θ[ ]obs × (MRW /10lc)                                         (2.1) 
where [θ]obs is the ellipticity measured in millidegrees, MRW is the mean residue 
molecular weight of the polypeptide (molecular weight of the peptide divided by the 
number of amino acid residues), l is the optical path length of the cell in cm (0.1 cm), and 
c is the peptide concentration in mgmL-1. 
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M n (kDa) 
 
€ 
M w /M n  # of grafts per copolymer 
PMaCC3 55.2 1.6 6.0 
PMaCC4 57.8 1.5 6.7 
PMaCC5 41.9 1.3 8.1 
P, polymer.
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2.3.5. Microrheology 
        Microrheology measures the mechanical properties of a material by monitoring the 
motion of micrometer-sized tracer particles in small sample volumes (usually less than 10 
µL). In passive microrheology, there is no external driving force applied to the tracer 
particles; the intrinsic Brownian motion of the particles is used, driven by thermal energy 
(kBT). The theoretical basis for passive microrheology is a generalized Stokes-Einstein 
relation (GSER) for materials with viscoelastic properties (30, 31), and can be presented 
in the following form: 
€ 
Δ˜ r 2(s) = dkBT3πas ˜ G (s)                                                  (2.2) 
where 
€ 
Δ˜ r 2(s)  is the Laplace transform of the tracer particles’ mean-squared displace-
ment (MSD) 
€ 
(r(t +τ ) − r(t))2 , d is the dimensionality of the displacement vector 
(usually 2 in video-microscopy), s is the Laplace frequency, a is the radius of the 
particles and 
€ 
˜ G (s) is the Laplace representation of the complex modulus, which 
encompasses the storage G’ and loss G’’ moduli. 
        Self-assembly of hydrogels (Figure 2.1) was examined in the presence of a 
suspension of fluorescently labeled latex beads (radius 0.5 µm, surfactant-free yellow-
green fluorescent amidine-modified microspheres). The copolymer (10% w/v) was 
dissolved in DMSO/H2O (50 vol.%), and latex beads were added and evenly mixed, then 
the sample was sealed between a microscope slide and a No. 1.5 glass cover slip with 
CytosealTM 60. Brownian motion of the embedded particles under particular experimental 
conditions (concentration, temperature and pH) was monitored with an epifluorescence 
optical microscope (Nikon Eclipse E800) using a 100×, NA=1.3, oil-immersion objective 
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and a CCD camera (Dage-MTI, DC330) with an exposure time of 2 msec. To avoid wall 
effects, the focus plane was set at least 20 µm into the sample chambers. For each sample, 
3,000 images were recorded using StreamPix software (Norpix Inc.) at intervals of 33 ms. 
Images then were analyzed with IDL image analysis software (Research Systems Inc, 
Boulder, CO) and the trajectories of the particles were extracted using algorithms 
developed and kindly provided by Crocker and co-workers (32). 
 
2.3.6. Dynamic light scattering (DLS) 
        DLS studies were conducted using a Brookhaven BI-200SM goniometer and BI-
9000AT digital correlator equipped with a He-Ne laser (λ=633 nm). Different 
concentrations of PMaCC5 in deionized (DI) water were measured at 10 oC and selected 
samples were then measured at different temperatures (4-62 oC) to elucidate the 
temperature dependence of gel cluster formation. The time correlation functions of the 
scattered intensity G(2)(t), where t is the delay time, were analyzed using the inverse 
Laplace transformation technique (the REPES (33) analysis in the program GENDIST in 
this case) to calculate the distribution function of relaxation times, τ. 
        Since the REPES analysis has a tendency to split broad distributions into two or 
more contributions (overfitting), the correlation functions were also fitted to a stretched 
exponential function with an exponent β. The exponent β (0≤ β ≤1) is interpreted as a 
measure of the width of the corresponding distribution of relaxation times, τ: the smaller 
is the value of β, the broader is the distribution. The mean relaxation time is given by, 
τc=(τ0/β)Γ(1/β), where τ0 is the effective relaxation time obtained from force fitting to a 
stretched exponential function and Γ(1/β) is the gamma function. DLS results were 
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presented using a plot of normalized intensity correlation function, g(2)(t)-1 versus log(t). 
The apparent hydrodynamic radius (Rh) was calculated from the mean relaxation time τc 
via the Stokes-Einstein equation: 
Rh=kBTq2τc/6πη                                                    (2.3) 
where kB is the Boltzmann constant, T is the absolute temperature, q is the scattering 
vector (q=4πnssin(θ/2)/λ, where ns is the refractive index of the solvent, θ is the 
scattering angle, and λ is the wavelength of incident laser light in vacuum), and η is the 
solvent viscosity. Repeated measurements were undertaken for each sample in order to 
calculate an average hydrodynamic radius.  
        Since the position of g(2)(t)-1plot on the x axis depends not only on the Rh of 
particles but also on temperature T and solvent viscosity η(T), we used a comparison of 
time correlation functions measured at different temperatures, a new variable t’=tT/η, to 
replace the delay time t. In this new plot, the position of g(2)(t’)-1 on the x axis (t’) is only 
related to temperature-induced variations of the mean Rh of particles. 
 
2.4. Results and discussion 
        HPMA copolymers composed of various macromonomers, such as methacryloylated 
α-methoxypoly(ethylene glycol) (34) and polymerizable antibody fragments (24) have 
been reported previously. Here, new macromonomers containing 3, 4 and 5 coiled-coil 
forming haptads were synthesized. The fact that both HPMA and the macromonomers 
contain methacryloyl groups as polymerizable components ensures the compatibility of 
comonomers in free radical copolymerization. 
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2.4.1. Design, synthesis and copolymerization of macromonomers 
        The design of macromonomers was based on the well-characterized heptad 
VSSLESK. A model peptide (EK42), composed of six VSSLESK heptads, forms parallel 
homodimers at room temperature and neutral pH (35). To reveal the structure-property 
relationship, peptides containing 3, 4 and 5 heptads were chosen for evaluation. Two 
structural modifications were exercised to the EK42 structure (13). To promote “in-
register” alignment of the peptide domains, valine in position a of the second heptad was 
substituted with lysine. In addition, serine residues in all c positions were replaced by 
lysine. The latter might destabilize the coiled-coil by electrostatic repulsion between the c 
and g positions on the same strand to achieve better responsiveness of hydrogels to 
temperature change. 
        In a previous publication, the peptides were capped at N-termini with CGG (13). 
This permitted their attachment to HPMA copolymers containing maleimido end-groups 
on side chains. To create macromonomers, N-termini of the peptides were capped with N-
methacryloylglycylglycyltryptophan (MaGGW, Table 2.1). 
        HPMA graft copolymers, PMaCC3, PMaCC4 and PMaCC5, were prepared by 
radical polymerization using a water-soluble azoinitiator, VA044. The copolymerization 
proceeded to a high conversion and yield (70–80%) of the copolymers. Although the 
macromonomers contained peptides of different lengths (3, 4 or 5 heptads), a similar 
content of grafts per copolymer was observed. This seems to indicate that the impact of 
the length of the oligopeptide sequence on the polymerization process was minor. 
However, the content of grafts in the final copolymer was lower than that in the feeding. 
Due to the reactivity difference between HPMA and macromonomers, the graft 
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copolymers may possess two levels of heterogeneity: a distribution of molecular weights 
and distribution of chemical composition. 
 
2.4.2. Secondary structure of peptides in macromonomers 
and HPMA copolymers  
        Secondary structure of peptides in macromonomers and copolymers was evaluated 
by CD spectrometry under benign conditions (5×10-2 M Na2HPO4/ NaH2PO4, 0.1 M KCl, 
pH=7). CD spectrum of interacting coiled-coil motifs has a characteristic feature of 
double negative peaks at 208 and 222 nm respectively, demonstrating an α-helical 
secondary structure (36). The molar ellipticity at 222 nm can be used to estimate the 
content of the helical structure present in a peptide (37). A ratio of ellipticity at 222 
versus 208 nm ([θ]222/[θ]208) close to 1 is an indication of strong interaction of α-helices, 
which leads to coiled-coil formation in our case (13). Wavelength scans indicated that the 
helical content of MaCC3, MaCC4 and MaCC5 were 6.62, 8.02 and 8.51%, respectively 
(38). As the chain length increased, the ellipticity at 222 nm tended to gradually increase. 
This suggested that all three peptides were essentially in the unfolded state under benign 
conditions at room temperature (Figure 2.2). This proved the contribution of the sequence 
modification that described above, as the secondary structure of (VSSLESK)x showed a 
typical pattern of α-helical structure when x was 5. To investigate whether these peptides 
had the potential to fold into α-helices (or the maximum possible helical content), CD 
spectra of macromonomers were also examined in the presence of 50% TFE. TFE has 
been shown to disrupt tertiary and quaternary structure but promote α-helix formation as 
a monomeric molecule.  Corresponding  spectra showed that their molar ellipticity at  222  
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Figure 2.2. CD spectra of macromonomers under benign conditions. The spectra were 
recorded at 25 oC in 5×10-2 M Na2HPO4/NaH2PO4, 0.1 M KCl, pH=7.0. Peptide 
concentrations were approximately 10-4 M. 
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nm became considerably more negative (Figure 2.3), a phenomenon suggested that the 
peptides are capable of forming highly helical structures (e.g., MaCC5 28.8%). 
Incorporation of the macromonomers into HPMA graft copolymers resulted in an 
increase of α-helical content, especially in the case of PMaCC5, compared to free 
peptides (Figure 2.4). Addition of 50% of TFE could further enhance this effect. This 
result is in a good agreement with the observed secondary structure of (VSSLESK)x and 
PEG2000-(VSSLESK)x diblock copolymers (27). Moreover, HPMA graft copolymers 
prepared by two different methods, polymer-analogous reaction (13) and macromonomer 
copolymerization, possessed similar properties. This implied that the distribution of grafts 
along the polymer backbone is similar for graft copolymers constructed from either 
synthetic pathway. Alternatively, the techniques used for the analysis of copolymer 
properties may not be sensitive enough to detect minor changes in the distribution of 
grafts along the HPMA copolymer backbone. 
 
2.4.3. Self-assembly of HPMA graft copolymers into hydrogels 
        The impact of heptad number on the self-assembly of HPMA graft copolymers into 
hydrogels was evaluated by microrheology and dynamic light scattering. Microrheology 
relies on the measurement of thermally induced Brownian motion of micrometer-size 
tracer particles dispersed in the samples. MSD of tracer particles increases linearly with 
time in a viscous solution. In a hydrogel, the motion of the embedded tracer particles is 
confined, which results in constant MSDs, independent of lag time.  
        The number of heptads in PMaCC3 was too low to mediate the self-assembly of the 
copolymer into  three-dimensional structures;  the MSD continuously increased with time 
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Figure 2.3. CD spectra of macromonomers in 50% of the α-helix enhancing agent TFE. 
The spectra were recorded at 25 oC in 5×10-2 M Na2HPO4/NaH2PO4, 0.1 M KCl, pH=7.0. 
Peptide concentrations were approximately 10-4 M. TFE, trifluoroethanol. 
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Figure 2.4. Comparison of CD profiles: MaCC5, PMaCC5 and PMaCC5 50% of the α-
helix inducing solvent TFE. The spectra were recorded at 25 oC in 5×10-2 M Na2HPO4 
/NaH2PO4, 0.1 M KCl, pH=7.0. Peptide concentrations were approximately 10-4 M. TFE, 
trifluoroethanol. 
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(Figure 2.5). However, the MSD of PMaCC4 and PMaCC5 were found to become 
constant with time, indicating self-assembly into hydrogels. The results of CD 
measurements (Figure 2.4) suggested that only for PMaCC5 was the self-assembly 
mediated by coiled-coil formation. In PMaCC4, non-specific interactions probably led to 
the self-assembly since there was no α-helical structure in the peptide domain observed 
by CD. As discussed before, the structure of the hydrogels is delicate, the oligopeptide 
sequences may form inter- and intra-molecular parallel homodimers. Cross-linking would 
then occur by the formation of tetramers and higher order aggregates (6). For these 
structures, the steric hindrance of the polymer backbone on self-assembly becomes an 
important factor. Recently, it was shown that the design of HPMA copolymers containing 
oppositely charged sequences forming anti-parallel heterodimers could minimize steric 
hindrance (14). 
        Dynamic light scattering is a method suitable for the characterization of 
nanoparticles and the evaluation of the time-dependence of the self-assembly. Therefore, 
the effect of temperature and polymer concentration on the self-assembly of PMaCC5 
into hydrogel clusters (nanoparticles, aggregates) was investigated by DLS. The 
normalized intensity autocorrelation function, g(2)(t), for solutions of PMaCC5 was 
plotted as a function of log(t) for different graft copolymer concentrations, c=1.38, 2.76, 
5.52, 8.00 and 9.20 mgmL-1, in Figure 2.6a. All samples used for the measurement of 
concentration dependence were not filtered in order to keep them comparable since there 
was a small portion of large particles present in high concentration sample solutions (i.e., 
8.00 and 9.20 mgmL-1). Correlation function profiles changed with increasing 
concentrations  from  sharp ones  at low  concentrations  to a  broad  one,  extending over 
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Figure 2.5. Mean-square displacement (MSD) as a function of lag time for 0.5 µm 
amidine-modified latex beads in 50 vol.% DMSO/H2O. Also shown is a control solution 
of polyHPMA (o). 
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 several orders of magnitude of t, at the highest concentration. The mean hydrodynamic 
radii of the polymer clusters, Rh, as calculated from results obtained by fitting of the time 
correlation functions in Figure 2.6a to a stretched exponential function were shown in 
Figure 2.6b. The particle size was independent of concentration at low concentrations and 
dramatically increased as concentration increased above 5.52 mgmL-1. The β value was 
about 0.90 at low concentrations and decreased to 0.75 at c=9.20 mgmL-1. These results 
strongly indicated the self-assembly of copolymers into clusters and underscored the 
importance  of  polymer  concentration  in  this process. A formation of large aggregates 
(about 1 µm) was observed at c=9.20 mgmL-1. These data are in agreement with the 
results of the random association of synthetic block copolymers in selective solvents (39), 
and with the self-assembly of graft copolymers containing sequences forming anti-
parallel heterodimers (40). 
        The normalized intensity autocorrelation functions were also measured for 5.52 
mgmL-1 PMaCC5 at temperatures ranging from 4 to 62 oC and g(2)(t’) results were 
plotted as a function of log(tT/η) (Figure 2.7a). The autocorrelation functions shifted 
gradually as temperature increased to higher t’ values reflecting the increase of Rh with 
increasing temperature. This demonstrated the effect of temperature on the association: as 
temperature went up, the collision probability of grafts also increased, so that the self-
assembly of copolymers was more effective at higher temperatures. The temperature 
dependence of average Rh values, as obtained by the force fitting of the correlation 
functions from Figure 2.7a to a stretched exponential function, was shown in Figure 2.7b. 
Rh increased with increasing temperature while β values were practically independent of 
temperature, β=0.7±0.02. 
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Figure 2.6. Concentration-dependence of PMaCC5 gel formation. a) Normalized intensity 
autocorrelation functions, g(2)(t)-1, at a scattering angle of 90o, for aqueous solutions of 
PMaCC5 at 10 oC. Concentrations of graft co-polymer were: (1) 1.38, (2) 2.76, (3) 5.52, 
(4) 8.00, (5) 9.20 mgmL-1. b) Concentration dependence of the hydrodynamic radii Rh of 
polymer clusters. Rh values were obtained from correlation functions in a) by force fitting 
to a stretched exponential function. 
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Figure 2.7. Temperature-dependence of PMaCC5 gel formation. a) Normalized intensity 
autocorrelation functions, g(2)(t’)-1, at scattering angle of 90o, for aqueous solution of 
PMaCC5 (5.54 mgmL-1) at different temperatures: (1) 4, (2) 15, (3) 25, (4) 45, (5) 62 oC. 
b) Temperature dependence of the hydrodynamic radii Rh of polymer clusters. Rh values 
were deduced from correlation functions in a) by force fitting to a stretched exponential 
function. 
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        By comparing the Rh and β values acquired from concentration and temperature 
measurements via DLS, we observed a minor discrepancy. This could be the result of 
sample preparation during the experiments. The solutions used for the concentration-
dependence measurement were not filtered as pointed out above; while the one for 
temperature-dependence measurement was filtered through a 0.45 µm membrane. 
Nevertheless, this would not influence the trends observed in the experiments. 
 
2.5. Conclusion 
        New macromonomers, containing 3, 4 and 5 heptads of coiled-coil forming motifs, 
were designed and synthesized. Free radical macromonomer copolymerization with 
HPMA produced hybrid graft copolymers composed of a linear HPMA copolymer 
backbone and coiled-coil motifs as grafts. The self-assembly of graft copolymers was 
evaluated by microrheology and DLS. Results showed that four heptads were the 
minimum for sufficient self-assembly. CD spectra of graft copolymer solutions and self-
assembly data indicated that five heptads were required for self-assembly mediated by 
coiled-coil formation. DLS data on self-assembly of PMaCC5 demonstrated the impact of 
graft copolymer concentration and temperature on self-assembly. 
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DRUG-FREE MACROMOLECULAR THERAPEUTICS: INDUCTION OF 
APOPTOSIS BY COILED-COIL-MEDIATED CROSS-LINKING 
 OF ANTIGENS ON CELL SURFACE 
 
3.1. Summary 
        Molecular biorecognition is at the heart of all biological processes and the design of 
precisely defined smart systems. Here we hypothesized that a unique biorecognition of 
two complementary coiled-coil motifs, CCE and CCK, could be employed to mediate a 
therapeutic effect for B-cell NHL. To this end, a binary system was designed, composed 
of polyHPMA copolymer grafted with multiple copies of CCK and Fab’ fragment of 1F5 
anti-CD20 antibody conjugated with CCE. Both conjugates were well characterized using 
various biophysical techniques and their in vitro efficacy was evaluated on Raji B cells. 
The multivalent effect during the heterodimerization of CCE and CCK and subsequent 
cross-linking of CD20 antigens led to a clinically relevant magnitude of B-cell apoptosis. 
This bodes well for the development of novel drug-free macromolecular therapeutics. 
________________________________________________________________________  
Note: This chapter is reprinted with permission from the following publication: Wu, K., 
Liu, J., Johnson, R. N., Yang, J., and Kopeček, J. (2010) Drug-free macromolecular 
therapeutics: Induction of apoptosis by coiled-coil mediated cross-linking of antigens on 
the cell surface. Angew Chem Int Ed 49, 1451-1455.  
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3.2. Introduction 
        Molecular biorecognition is at the center of all biological processes and forms the 
basis for the design of precisely defined smart systems, including targeted therapeutics, 
imaging agents, biosensors, and stimuli-sensitive and self-assembled biomaterials. The 
self-assembly of hybrid materials composed of synthetic and biological macromolecules 
is mediated by the biorecognition of biological motifs (1-4). We have previously 
designed self-assembling hybrid hydrogel systems composed of a synthetic N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymer backbone and coiled-coil peptide 
motifs; our results showed that it is possible to impose properties of a well-defined 
coiled-coil peptide on a whole hybrid hydrogel (5). Recently, we designed a pair of 
oppositely charged pentaheptad peptides (CCE and CCK) that formed anti-parallel 
coiled-coil heterodimers and served as physical cross-linkers (6). HPMA graft 
copolymers CCE–P and CCK–P (P is the HPMA copolymer backbone) self-assembled 
into hybrid hydrogels with a high degree of biorecognition (6, 7). 
        We hypothesized that this unique biorecognition of CCK and CCE peptide motifs 
could be extended beyond biomaterials design and applied to a living system to mediate a 
biological process. This approach would provide a bridge between the design of 
biomaterials and the design of macromolecular therapeutics. 
        To verify this hypothesis, we chose to study the induction of apoptosis in CD20- 
positive cells. CD20 is one of the most reliable biomarkers for B-cell non-Hodgkin’s 
lymphoma (NHL) (8, 9). It functions as a cell-cycle-regulatory protein (10) that either 
controls or behaves as a store-operated calcium channel (11-13). CD20 also forms dimers 
and tetramers (11) constitutively associated with lipid rafts of the cell membrane (9). It is 
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a non-internalizing antigen that remains on the cell surface when bound to a 
complementary antibody (Ab) (14). However, the cross-linking of CD20-bound 
antibodies with a secondary antibody results in apoptosis (15). To exploit this 
phenomenon, we designed a system composed of CCE and CCK peptides, the Fab’ 
fragment of the 1F5 anti-CD20 antibody, and HPMA copolymer (Figure 3.1). The 
exposure of CD20+ Raji B cells to Fab’-CCE resulted in the decoration of the cell surface 
with multiple copies of the CCE peptide through antigen-antibody-fragment 
biorecognition. Further exposure of the decorated cells to HPMA copolymer grafted with 
multiple copies of CCK resulted in the formation of CCE–CCK coiled-coil heterodimers 
on the cell surface. This second biorecognition event induced the cross-linking of CD20 
receptors and triggered the apoptosis of Raji B cells. 
 
3.3. Materials and methods 
3.3.1. Materials 
        Side-chain protected Fmoc-amino acids, 2-chlorotrityl resin, 2-(1H-benzotriazol-1-
yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), and ethanedithiol  (EDT) 
were purchased from Novabiochem (San Diego, CA). Dimethyl sulfoxide (DMSO) was 
purchased from EMD Chemicals, Inc. (Gibbstown, NJ). Dimethylformamide (DMF), 
trifluoroacetic acid (TFA), and methanol were purchased from VWR International (West 
Chester, PA). 2,2’-azobisisobutyronitrile (AIBN) and succinimidyl-4-(N-maleimido-
methyl)cyclohexane-1-carboxylate (SMCC) were purchased from Soltec Ventures 
(Beverly, MA). Tris(2-carboxyethyl) phosphine hydrochloride (TCEP) was purchased 
from Thermo Scientific (Waltham, MA).  N,N-diisopropylethylamine (DIPEA), peridine,
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Figure 3.1. Induction of apoptosis in human Burkitt’s NHL Raji B cells by cross-linking of its CD20 antigens mediated by coiled-coil 
formation on the cell surface. 
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O-phthaldialdehyde (OPA), triisopropylsilane (TIS) and 3-mercaptopropionic acid 
(MPA) were purchased from Sigma Aldrich (St. Louis, MO). Dichloromethane (DCM) 
was purchase from Mallinckrodt Chemicals (Phillipsburg, NJ). HPMA (16) and N-
methacryloylaminopropyl fluorescein thiourea (MA-FITC) (17) were synthesized as 
previously reported. 
 
3.3.2. Sequence design and synthesis of CCE and CCK 
3.3.2.1. Sequence design 
        We recently designed two oppositely charged pentaheptad peptides, CCE and CCK 
(Figure 3.2), that self-assembled into anti-parallel coiled-coil heterodimers (6). Three 
major stabilizing interactions were the hallmarks of the design: the hydrophobic 
interactions in the core, electrostatic interactions across the interface, and helical 
propensity effects (6). The coiled-coil sequences were extended at the N-terminus: a) the 
CCK peptide with a tetrapeptide spacer, CYGG, to permit its attachment as graft to N-(2-
hydropxypropyl)methacrylamide (HPMA) copolymer containing side chains terminated 
with maleimido groups via thioether bonds; b) the CCE peptide with maleimide-YGG to 
allow for the conjugation to SH groups of the Fab’ fragment. In addition, the insertion of 
spacers to both sequences would decrease the steric hindrance of the HPMA copolymer 
backbone and of the Fab’ fragment on the “in-register” arrangement of CCK-CCE anti-
parallel coiled-coil heterodimers. 
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Figure 3.2. Helical wheel representation of CCE/CCK coiled-coil anti-parellel 
heterodimers. The view was shown looking down the super-helical axis from the N-
terminus of CCE and from the C-terminus of CCK. The primary structure of the coiled-
coil motif is characterized by a heptad repeating sequence of amino acids designated as  
a-g. CC, coiled-coil; E and K sequences whose g positions are mainly occupied by 
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3.3.2.2. Peptide synthesis  
        CCE and CCK peptides were synthesized using solid-phase method following a 
manual Fmoc/tBu strategy on 2-chlorotrityl resin as described previously (6, 18). 
Synthesis of CCK: 2-chlorotrityl resin (500 mg, 1.3 mmolg-1 resin) was weighed and put 
into a 20 mL polypropylene syringe equipped with a bottom 20 µm polyethylene filter. 
The first residue (Fmoc-Glu(OtBu)-OH, 0.325 mmol, 138 mg, 50% loading) was 
dissolved in 10 mL DCM, followed by the addition of N,N-diisopropylethylamine 
(DIPEA; 4×, 1.30 mmol, 0.224 mL). This solution was added to the resin and the 
suspension was gently shaken for 1 h. The loaded resin was washed three times with 
DCM/MeOH/DIPEA (17:2:1), DCM, and DMF, respectively. After DMF was drained in 
vacuum, the loaded resin was deprotected twice with 2.5 mL of 20% piperidine in DMF 
for 10 min to remove the Fmoc protecting grop. Then the resin was washed thoroughly 
with DMF (3 times) and confirmed via positive Kaiser test. The second residue (Fmoc-
Lys(Boc)-OH, 2.5×1st residue, 0.81 mmol, 380.6 mg) and HBTU (0.9 × 2nd residue, 0.729 
mmol, 277 mg) were dissolved in 5 mL DMF, followed by DIPEA (4×, 3.25 mmol, 560 
µL). The mixture was added into the resin and gently shaken for 2-3 h at room 
temperature. The completeness of coupling was monitored also by the Kaiser test. The 
resin was then washed with DMF and deprotected as described above. The coupling 
reaction was repeated likewise untill the last amino acid residue, Fmoc-Cys(Trt)-OH. 
Cleavage of the peptide from the resin and deprotection of side-chain protecting groups 
was achieved simultaneously by incubating the resin with a cleavage cocktail (94.5% 
TFA, 2.5% H2O, 2.5% EDT and 1% TIS) for 2.5 h at room temperature under constant 
shaking. Upon removal of the cleaved resin, solvents were evaporated under reduced 
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pressure and the product was precipitated into cold ether. The crude peptide was retrieved 
after centrifugation at 3,000 rpm for 20 min and dried in vacuum. The CCK peptide was 
purified by preparative reversed-phase HPLC (RP-HPLC) and lyophilized. 
        CCE was synthesized following a similar protocol as CCK. To introduce the 
maleimido functional group to the N-terminus of CCE, SMCC, a hetero-bifunctional 
cross-linking agent, was coupled at the last step. A solution of SMCC (0.65 mmol, 217 
mg) and DIPEA (1.3 mmol, 224 µL) in 2.5 ml DMF was added to the peptide-bound 
resin (0.65mmol, 500 mg). The suspension was kept at room temperature for 6-12 h to 
allow for complete coupling under constant shaking. Then the peptide was cleaved from 
the resin using a TFA/TIS/H2O cocktail solution (95:2.5:2.5, vol.%), and the product was 
processed as described above. 
 
3.3.2.3. Peptide characterization 
        Crude peptides were purified by RP-HPLC equipped with a semi-preparative Zorbax 
300SB-C18 column (250×9.4 mm, 5 µm particle size, 300 Å pore size) from Agilent 
Technologies (Santa Clara, CA). The peptides were eluted with a linear gradient at a flow 
rate of 2 mLmin-1 with buffer A as 0.1% TFA in water and B as 0.1% TFA in 90/10 (v/v) 
methanol/H2O. The peptide structures were confirmed by MALDI-TOF mass 
spectrometry (Voyager-DE STR Biospectrometry Workstation, Perseptive Biosystems, 
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3.3.3. Synthesis of Fab’-(CCE)1 conjugate labeled  
with Rhodamine Red-X (RRX) 
3.3.3.1. Preparation of RRX labeled F(ab’)2 
        The murine 1F5 anti-CD20 IgG2a antibody (Ab) was prepared using the anti-CD20 
hybridoma clone 1F5 (19). The hybridoma clone (ATCC, Bethesda, MD) was initially 
cultured and recloned through limiting dilution in RPMI 1640 medium supplemented 
with 10% fetal bovine serum (FBS; Hyclone Laboratories, Logan, UT) in a humidified 
environment with 5% CO2 in air. The selected clone was adapted to chemically defined, 
serum-free media (Invitrogen, Carlsbad, CA). Adapted cells were used to seed a 
CellMax© bioreactor (Spectrum Laboratories, Rancho Dominguez, CA) according to the 
manufacturer’s instructions. Anti-CD20 mAb 1F5 was purified on a Protein G Sepharose 
4 Fast Flow column (GE Healthcare, Piscataway, NJ) from bioreactor harvest supernatant 
(20, 21).  
        As shown in Figure 3.3a, the 1F5 antibody was digested into F(ab)2 with lysyl 
endopeptidase (Wako Chemicals USA, Richmond, VA) as previously described. F(ab’)2 
was then labeled with RRX succinimidyl ester (Invitrogen, Carlsbad, CA) to introduce a 
fluorophore to facilitate the fluorescence microscopy investigation. Briefly, 40 µL of 
RRX succinimidyl ester solution (5 mM) in DMF was added into 3 mL of F(ab’)2 
solution (3 mgmL-1) in PBS (pH 7.4). Then the pH of the labeling mixture was gradually 
adjusted to 8.3 using 0.1 N NaOH under constant stirring. Additional 30 min were 
allowed to complete the labeling reaction. The labeled F(ab’)2 was then purified twice 
using a PD10 column (GE Healthcare, Buckinghamshire, UK) to remove the unreacted 
ester. To estimate the degree of labeling, a 10× diluted sample was scanned from 250-650 
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nm on Varian UV-Vis spectrophotometer (Varian Inc., Palo Alto, CA). The concentration 
of RRX was calculated using the absorbance at 585 nm with an extinction coefficient of 
63,000 cm-1M-1 in PBS; absorbance at 280 nm was used to deduce the molar 
concentration of F(ab’)2 using an empirical equation (c (mgmL-1) = A280nm/1.35) together 
with molecular weight. The ratio of these two molar concentrations gave a labeling 
degree of two RRX probes per F(ab’)2 molecule. 
 
3.3.3.2. Synthesis of Fab’-(CCE)1 
        Fab’-(CCE)1 was obtained by conjugation of Fab’ with CCE using maleimide-thiol 
chemistry. Immediately prior to use, the RRX labeled F(ab′)2 was reduced to Fab’ with 
10 mM TCEP in PBS (pH 7.4) containing 5 mM EDTA for 1 h at 37 oC in the dark. CCE 
(1.5× in excess to Fab’) was added and the coupling reaction proceeded at 4 oC in the 
dark overnight. The crude product was then purified twice using a PD10 column. As 
reported (22), this coupling reaction follows a 1:1 stoichiometry. Thus the resulting 
conjugate was named Fab’-(CCE)1. 
  
3.3.4. Synthesis of HPMA copolymer grafted with CCK ((CCK)9-P)(6) 
        The synthetic procedure consisted of three steps: first, a copolymer of HPMA and N-
(3-aminopropyl)methacrylamide (MA-NH2) was prepared by radical copolymerization in 
methanol at 50 oC with AIBN as the initiator. Then the amino groups at side-chain 
termini were converted to maleimido groups (polymer precursor) by reaction using 
SMCC. Finally, the CCK peptide flanked with a cysteine residue at the N-terminus was 
attached to the polymer precursor side-chains via thioether bonds (Figure 3.3b). 
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Figure 3.3. Synthetic schemes for the conjugates. a) Fab’-CCE and b) CCK-P.   
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Figure 3.3. Continued. 
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3.3.4.1. Copolymerization of HPMA with MA-NH2  
        HPMA (500 mg) and 40 mg MA-NH2 (molar ratio = 94:6) were dissolved in 
methanol together with AIBN  (0.6%  of the total weight of the  monomers),  and bubbled 
with nitrogen for 5 min before the ampoule was sealed. The copolymerization was 
allowed for 24 h at 50 oC. The crude product was precipitated into acetone, centrifuged, 
redissolved in methanol, re-precipitated into acetone, and dried under vacuum. The 
copolymer was further purified by dialysis against DI water to remove oligomers and 
unreacted monomers, and lyophilized. The copolymer yield was 76% and the amine 
content in the copolymer was 389 nmolmg-1 as determined by the ninhydrin test.  
        To introduce a fluorescent probe, a FITC labeled copolymer was prepared following 
a similar procedure using N-methacryloylaminopropyl fluorescein thiourea (MA-FITC) 
as an additional comonomer (the feeding ratio of HPMA : MA-NH2 : MA-FITC = 93.5 : 
6 : 0.5). The molecular weight and molecular weight distribution of the copolymer were 
measured on the ÄKTA FPLC system (Amersham Pharmacia Biotech, Piscataway, NJ) 
equipped with UV and RI detectors using a Superose 6HR10/30 column with PBS (pH= 
7.4) as the mobile phase using a calibration with linear polyHPMA fractions. The 
copolymer yield was 82% with an amine content of 397 nmolmg-1. The number average 
molecular weight was 99.6 kDa (
€ 
Mw /Mn= 2.05). 
 
3.3.4.2. Synthesis of HPMA polymer precursor with  
side-chains terminated in maleimide 
        The copolymer P-NH2 and SMCC (molar ratio [NH2] : [SMCC] = 1 : 1.5) were 
dissolved in DMF and the reaction was performed in the presence of triethylamine (TEA, 
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3× [NH2]) at room temperature overnight. After precipitation into acetone/ether (3:2), the 
product was redissolved in methanol and precipitated into acetone twice to remove 
unreacted SMCC. The maleimide content of the precursor was 259 nmolmg-1 as 
measured by the modified Ellman’s assay (23, 24). 
 
3.3.4.3. Attachment of CCK to polymer precursor - synthesis of CCK-P  
        Polymer precursor and CCK ([Mal] : [CCK] = 1 : 1) were dissolved in PBS (pH 7.4) 
containing  1  mM  EDTA,  and  the  coupling  reaction  proceeded  at  room  temperature 
overnight with analytical RP-HPLC monitoring the progress. The conjugate was then 
dialyzed against DI water using a dialysis tube with molecular weight cutoff 6-8 kDa to 
remove unreacted CCK; then lyophilized. 
        The graft content in the resulted copolymer was determined by amino acid analysis. 
The copolymer (2.08 mg) was hydrolyzed in 0.2 mL 6 N HCl at 120 oC for 16 h in a 
sealed ampoule and then dried under vacuum. A precolumn derivatization with o-
phthaldialdehyde (OPA) was used and the samples were analyzed by HPLC with 
fluorescence detector (excitation 229 nm and emission 450 nm) using a gradient elution 
with mixtures of buffer A and B, where buffer A: 0.05 M sodium acetate, pH 6.0, and B: 
70% methanol in buffer A [6]. The average number of CCK grafts per macromolecule 
was determined as 8.94. Thus, we denoted the HPMA copolymer grafted with CCK as 
(CCK)9-P. 
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3.3.5. Biorecognition of Fab’-(CCE)1 and (CCK)9-P in solution 
        To demonstrate the biorecognition between Fab’-(CCE)1 and (CCK)9-P, circular 
dichroism (CD) spectrometry and dynamic light scattering (DLS) were employed. The 
following samples were prepared in PBS (pH=7.4) for these measurements: CCE (50 
µM), CCK (50 µM), Fab’-(CCE)1 ([CCE]=50 µM), and (CCK)9-P ([CCK]=50 µM)). In 
this study, higher concentrations of CCE and CCK motifs were used than those in the 
apoptosis studies, because CD and DLS measurements require more sample mass to 
achieve an appropriate signal/noise ratio as to ensure accurate data acquisition. 
        CD spectra of individual samples (CCE, CCK, and (CCK)9-P) and equimolar 
mixtures (CCE+CCK, and Fab’-(CCE)1+(CCK)9-P) were acquired at 25 oC on an Aviv 
62DS CD spectrometer with a thermoelectric temperature control system (Aviv 
Biomedical, Lakewood, NJ). Wavelength scans were recorded at 1 nm intervals with a 5 
sec averaging time at each step from 250 to 200 nm using a 0.1 cm path length quartz 
cuvette. The spectra obtained were averaged from three consecutive scans and subtracted 
from the background. Ellipticity was reported as the mean residue ellipticity ([θ], in 
degcm2 dmol-1) calculated as: 
[θ ] = [θ ]obs(MRW /10lc)                                            (3.1) 
where [θ]obs is the ellipticity measured in millidegrees, MRW is the mean residue 
molecular weight of the polypeptide (molecular weight of the peptide divided by the 
number of amino acid residues), l is the optical path length of the cell in cm (0.1 cm in 
our case), and c is the peptide concentration in mgmL-1. 
        DLS studies were conducted on a Brookhaven BI-200SM goniometer and BI-
9000AT digital correlator with a He-Ne laser source (λ=633nm, Brookhaven Instruments 
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Corporation, Holtsville, NY). Individual samples (Fab’-(CCE)1 and (CCK)9-P) and equi-
molar mixture (Fab’-(CCE)1+(CCK)9-P) were applied and their effective diameters in nm 
were calculated by the digital correlator.  
 
3.3.6. Cell preparation and incubation with peptide conjugates  
        Human Burkitt’s B-cell non-Hodgkin’s lymphoma Raji cells (ATCC, Manassas VA) 
were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) 
at 37 oC in a humidified atmosphere of 5% CO2 (v/v) (25). Experiments were performed 
during the exponential growth phase of the cells. 
        Cells were treated with either consecutive addition or premixture of conjugates. For 
the consecutive addition, cells were firstly incubated with Fab’-(CCE)1 in growth 
medium containing 10% FBS at 37 oC for 1 h, then washed twice with sterile PBS 
(pH=7.4) containing 1% bovine serum albumin (BSA) to remove unbound conjugate; and 
secondly these pretreated cell pellets were re-suspended in FBS supplemented growth 
medium containing (CCK)9-P for various durations. For the treatment with premixture, 
Fab’-(CCE)1 and (CCK)9-P were first mixed in FBS containing growth medium in a  
sterilized test tube at 37 oC for 1 h, then cells were incubated with this premixture for 
different intervals. 
 
3.3.7. Visualization of biorecognition on Raji B-cell surface 
        Biorecognition between components of the binary system was visualized by 
confocal fluorescence microscopy. After incubation with Fab’-(CCE)1 and (CCK)9-P, 
using either consecutive addition or premixture (as described in 3.3.6), cells were washed 
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twice with PBS (pH=7.4). Then the cell suspensions were dropped onto glass bottom 
microwell dish (MetTek, Ashland, MA). FluoView1000-XY confocal Olympus IX81 
microscope (Olympus America, Center Valley, PA) was employed to visualize the cells. 
 
3.3.8. In vitro apoptosis evaluation 
        Apoptosis induction, mediated by coiled-coil formation at the cell surface with 
concomitant cross-linking of CD20 receptors, was evaluated by three methods: caspase 3 
activation, Annexin V/propidium iodide (PI) assay, and the TUNEL assay. For 
experimental details of these assays, please refer to the standard protocols from 
corresponding suppliers: caspase 3 activity assay (employing a cell permeable 
fluorogenic caspase 3 substrate PhiPhiLux®; OncoImmunin, Gaithersburg, MD), 
Annexin V/PI assay (Annexin V-FITC® apoptosis detection kit; EMD Chemicals, 
Gibbstown, NJ), and TUNEL (terminal deoxynucleotidyl transferase dUTP nick end 
labeling) assay (APO-BRDUTM® TUNEL assay kit; Phoenix Flow Systems, San Diego, 
CA). Per the requirement of different assays, cells were dispensed into 24-well cell 
culture plates: 2×105 cells in 400 µL medium for both caspase 3 activity and Annexin 
V/PI binding assays, and 1×106 cells in 500 µL medium for the TUNEL assay. 
        Conjugates were added into cell culture by two different approaches: either 
premixing or consecutive addition, as described in 3.3.6. Different molar ratios of Fab’- 
(CCE)1 to (CCK)9-P including 1:1, 1:10 and 1:25 ([CCE] was chosen as 1 µM, thus 
[CCK]=1, 10, and µM, respectively) were studied to achieve the maximum efficiency of 
apoptosis induction. To examine the cytoxicity of the individual components, cells were 
incubated with only Fab’-(CCE)1 or (CCK)9-P. In addition, to introduce a clinically 
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relevant reference, cells were incubated with consecutive addition of 1F5 Ab and goat 
anti-mouse secondary antibody (1F5+GAM) (26). The percentage of apoptotic cells were 
quantified with caspase 3 activity assay after different durations (6, 12, 18 and 24 h). 
According to this preliminary experiment, other combinations for various durations of 
incubation were also examined with aforementioned all three different assays.  
        Last but not the least, to evaluate the critical role of the coiled-coil motifs in the 
system, a series of control experiments were conducted, as shown in Table 3.1. 
Concentrations of different species were adjusted to equivalent of [CCE]=1 µM or 
[CCK]=25 µM. 
 
3.4. Results and discussion 
3.4.1. Characterization of coiled-coil motifs  
        A good agreement between theoretical and measured molecular weights of CCE and 
CCK was observed (Figure 3.4a and b). CCE: calculated 4312.8 Da, found 4313.3 Da; 
CCK: calculated 4179.8 Da, found 4180.1 Da. The purity of the peptides was verified 
with analytical RP-HPLC. Results (Figure 3.4c and d) indicated that the purity of 
peptides was > 95%. 
 
3.4.2. Conjugation of Fab’ and CCE 
        The digestion of 1F5 whole antibody to its Fab’ fragment and the further 
conjugation were closely monitored and confirmed by size exclusion chromatography 
(SEC), sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and RP-
HPLC. 1F5 Ab, F(ab’)2, Fab’ fragment, and Fab’-(CCE)1 were individually injected into  
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Table 3.1. Facts of control experiments 
Approach Name Components Rationale 
Pre 6 h C1 Fab’+CCE+CCK+P-NH2 
Pre 6 h C2 Fab’-(CCE)1+ P-NH2 
Premixing 
Pre 6 h C3 Fab’+(CCK)9-P 
Con 24 h C1 Fab’+CCE, then CCK+P-NH2 
Con 24 h C2 Fab’-(CCE)1, then P-NH2 
Consecutive 
addition 
Con 24 h C3 Fab’, then (CCK)9-P 
To prove: CCE/CCK 
heterodimerization 
without conjugation was 
not sufficient; however, 
it is necessary for 
apoptosis induction. 
Pre, premixture; C, control; Con, consecutive.





















Figure 3.4. Profiles of peptides by MALDI-TOF MS and RP-HPLC. a and b) MALDI-
TOF MS spectra for CCE and CCK, respectively; c and d) HPLC profiles of pure CCE 
and CCK, respectively.     
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a SEC column and different characteristic elution times were observed (Figure 3.5a). 
SDS-PAGE demonstrated the successful digestion of 1F5 antibody and conjugation of 
Fab’ fragment with CCE (Figure 3.5b). The HPLC profiles of Fab’ and Fab’-(CCE)1 
were shown in Figure 3.5c. 
 
3.4.3. Biorecognition of the conjugates in solution 
        The biorecognition of Fab’-(CCE)1 and (CCK)9-P was first evaluated by circular 
dichroism (CD) spectrometry. A pronounced coiled-coil signal (minima at 208 and 222 
nm) was observed upon the mixing CCE or Fab’-(CCE)1 with (CCK)9-P (Figure 3.6), 
where   the molar ratio was adjusted to ensure equimolar of the peptide  motifs.  Dynamic 
light scattering (DLS) measurements revealed that the size of the individual components 
did not change within the tested period of 1 h: 6.6 and 51.7 nm for Fab’-(CCE)1and 
(CCE)9-P, respectively (Figure 3.7); however, the effective diameter of particles in the 
equimolar mixture of Fab’-(CCE)1 and (CCK)9-P increased significantly, which strongly 
implied the self-assembly/biorecogintion of the two conjugates.  
 
3.4.4. Biorecognition of the conjugates on B-cell surface 
        The exposure of Raji B cells to Fab’-(CCE)1 led to decoration of the cell surface 
with the CCE peptide, as shown by confocal fluorescence microscopy (Figure 3.8a). In 
contrast, the exposure of Raji B cells to (CCK)9-P did not result in detectable deposition 
of the graft copolymer at the cell surface under the experimental conditions used (Figure 
3.8b). The exposure of Raji B cells to a high-avidity multivalent construct prepared by 
the premixing of Fab’-(CCE)1 and (CCK)9-P resulted in excellent binding to the cell 




















Figure 3.5. Monitoring of antibody digestion and Fab’ fragment conjugation with CCE 
peptide. a) SEC profiles of separately injected 1F5 Ab, F(ab’)2, Fab’, and Fab’-(CCE)1 on 
Superdex 200 analytical column eluted with PBS (pH=7.4). b) SDS-PAGE of molecular 
weight standards (Lane 1), 1F5 Ab (150 kDa; Lane 2), F(ab’)2 (100 kDa; Lane 3), Fab’-
(CCE)1 conjugate (54 kDa; Lane 4), and Fab’ fragment (50 kDa; Lane 5). c) Analytical 
RP-HPLC profiles of Fab’ fragment and Fab’-(CCE)1; Agilent Zorbax 300SB-C18 
column (4.6×250 mm) eluted with a gradient of buffer A (H2O+0.1% TFA) and buffer B 
(acetonitrile + 0.1% TFA). 
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Figure 3.6. CD spectra of CCE, CCK, (CCK)9-P, and equimolar mixtures of CCE and 
(CCK)9-P, and Fab’-(CCE)1 and (CCK)9-P. [CCE]=[CCK]=[Fab’-(CCE)1]=50 µM; 
[(CCK)9-P]=5.60 µM. Data were acquired at 25 oC in PBS (pH=7.4).  
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Figure 3.7. Effective diameters of Fab'-(CCE)1 and (CCK)9-P and the effective diameter 
growth upon mixing equimolar amounts of them, as determined by DLS. Concentrations: 
[CCE]=[CCK]=[Fab’-(CCE)1]=50 µM; [(CCK)9-P]=5.60 µM. Data were acquired at 25 
oC in PBS (pH=7.4). 
 
	   131	  
surface (Figure 3.8c1–c3). This result was in agreement with our studies on the interaction 
of CD20 with multivalent HPMA copolymer-Fab’ conjugates (21). Finally, the exposure 
of Raji B cells predecorated with the CCE peptide to (CCK)9-P (consecutive exposure) 
resulted in the attachment of (CCK)9-P to the cell surface (Figure 3.8d1–d3). This result 
suggested  that coiled-coil  heterodimers were formed at the cell surface.  It demonstrated 
outstanding biorecognition between CCE bound to the cell surface and CCK grafted onto 
the HPMA copolymer.         
        Fab’-(CCE)1 remained on the cell surface even after 6 h for all treatments. Although 
extra time was given, there was no visible (CCK)9-P bound to the cell surface in the 
absence of Fab’-(CCE)1 (Figure 3.9a). The surface fluorescence intensity was stronger in 
cells exposed to premixed conjugates, compared to conjugates consecutively added. 
Figure 3.9b compared the biorecognition when cells were consecutively incubated with 
Fab’-(CCE)1 and (CCK)9-P dissolved in either PBS or growth medium containing FBS 
for 1 h. Results showed that the presence of FBS did not interfere with the biorecognition 
between Fab’-(CCE)1 and (CCK)9-P; on the contrary, a slightly better biorecognition was 
observed, probably due to sufficient nutrition for the cells. 
 
3.4.5. Apoptosis induction 
        The caspase 3 activity assay was first used to evaluate the time-dependence of 
apoptosis induction (Figure 3.10). The exposure of cells to the individual components 
Fab’-(CCE)1 or (CCK)9-P resulted in a very low percentage of cell death, independent of 
the incubation interval. However, a time-dependence was observed for the coiled-coil- 
based apoptosis-induction systems: treatment with a mixture of Fab’-(CCE)1 and (CCK)9-
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Figure 3.8. Biorecognition of Fab’-(CCE)1 and (CCK)9-P on the surface of Raji B cells 
(r1, r2 : reference cells under transmitted light). a) The exposure of cells to Fab’-(CCE)1 
(0.5 µM, labeled with Rhodamine Red-X) resulted in decoration of the cell surface with 
CCE. b) The exposure of cells to (CCK)9-P ([CCK]=25 µM, labeled with FITC) did not 
result in staining. c1-c3) Exposure of cells to premixed Fab’-(CCE)1 (0.5 µM ) and 
(CCK)9-P ([CCK]=25 µM). d1-d3) Consecutive exposure of cells to Fab’-(CCE)1 (0.5 µM) 
followed (1 h later) by (CCK)9-P ([CCK]=25 µM). a, c1, and d1: red channel for 
Rhodamine Red-X; b, c2, and d2 : green channel for FITC; c3 and d3: overlay of red and 
green channels. Images of individual cells are shown. 


















Figure 3.9. The influence of incubation duration and medium on cell surface staining by 
the conjugates. a) Confocal fluorescence microscopy images of Raji B cells exposed to 
Fab’-(CCE)1 and (CCK)9-P for different durations (2-6 h). R: red channel; G: green 
channel; O: overlay of R and G. Fab’-(CCE)1: Cells incubated with Fab’-(CCE)1 (500 
nM, Rhodamine-Red-X labeled) only; (CCK)9-P: cells incubated with (CCK)9-P 
([CCK]=25 µM, FITC labeled) only - no staining; Pre: cells incubated with a premixture 
of Fab’-(CCE)1 (500 nM) and (CCK)9-P ([CCK]=25 µM); Cons: cells incubated with 
Fab’-(CCE)1 (500 nM) for 1 h followed by (CCK)9-P ([CCK]=25 µM) for 6 h. b) 
Comparison of cell staining in the presence (medium; upper panel) or absence (PBS; 
lower panel) of FBS. Cells incubated with Fab’-(CCE)1 (500 nM) for 1 h followed by 
(CCK)9-P ([CCK]=25 µM) for 6 h. 
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Figure 3.10. Time dependence of apoptosis induction in Raji B cells via caspase 3 
activity assay. Untreated: untreated cells; Fab’-(CCE)1: single-component control at 0.5 
µM; (CCK)9-P: single-component control ([CCK]=25 µM); 1F5+GAM: addition of 1F5 
Ab (0.2 µM) followed (1 h later) by the secondary antibody GAM (10 mg µL-1); 
premixed: premixture of Fab’-(CCE)1 (0.5 µM) and (CCK)9-P ([CCK]=25 µM ); 
consecutive: consecutive addition of Fab’-(CCE)1 (0.5 µM) followed (1 h later) by 
(CCK)9-P ([CCK]=25 µM). Results are presented as mean values ± standard deviation 
(n=3). 
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P, and the consecutive exposure of cells to Fab’-(CCE)1 followed by (CCK)9-P. The 
highest levels of apoptosis after incubation for 6 hours were observed with premixed 
Fab’-(CCE)1 and (CCK)9-P; whereas for both consecutive-addition systems, Fab’-(CCE)1  
+ (CCK)9-P and the control 1F5 + goat antimouse (GAM) secondary antibody, the extent 
of apoptosis  increased with increasing  incubation time,  with  the highest  level observed 
after 24 h. These results probably reflect different levels of destabilization of the plasma-
membrane integrity following exposure to a multivalent high-avidity conjugate versus a 
monovalent Fab’-(CCE)1 conjugate. 
          Apoptosis induction by exposure of Raji B cells to a premixture or consecutive 
addition of Fab’-(CCE)1+(CCK)9-P with different molar  ratios of  [CCE] : [CCK] (1:1, 
1:10, 1:25) was also examined by all three quantification methods. Results were 
summarized in Figures 3.11 and 3.12. As shown, the ratio of 1:25 resulted in highest 
efficiency in apoptosis induction. Compared with the single component, all binary 
systems produced higher levels of apoptosis; the levels increased with the increase of 
(CCK)9-P excess. This is not surprising, since only some of the grafts in (CCK)9-P 
participate in formation of  anti-parallel coiled-coils due to the fact that the  accessibility 
of the peptide grafts attached to the HPMA copolymer is restricted. The efficiency of 
coiled-coil formation depends on the binding constant between CCE and CCK, the 
number of grafts in conjugate and flexibility of the polymer backbone. Additionally, a 
portion of (CCK)9-P may be nonspecifically attached to the cell surface or proteins in the 
medium. Fortunately, such an attachment did not result in apoptosis induction as results 
shown in Figure 3.11. The nonspecific attachment can be avoided in the future by using a 
system composed of Fab’-CCK and graft copolymer CCE-P. The negative charge of 



















Figure 3.11. Apoptosis induction in Raji B cells by Fab’-(CCE)1 and (CCK)9-P at 
different ratios of [CCE]:[CCK] (1:1 and 1:10) for various durations (6, 12 and 24 h). 
Cells were exposed to either premixed (Pre) or consecutively added (Cons) Fab’-(CCE)1 
and (CCK)9-P. Percentage of apoptotic cells was quantified by caspase 3 activation assay 
(a and b), Annexin V assay (c and d), and TUNEL assay (e and f), respectively. Fab’-
CCE)1 concentration kept 1 µM; the concentrations of (CCK)9-P were adjusted to 
[CCK]=1 and 10 µM for ratios of 1:1 and 1:10, respectively. Results are presented as 
mean values ± standard deviation (n=3). 
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Figure 3.12. Coiled-coil-mediated induction of apoptosis of Raji B cells, as assessed by: 
a) caspase 3 activity, b) annexin V/PI staining assay, and c) TUNEL assay. The 
concentrations of 1F5 and GAM were 0.2 µM and 10 mgmL-1, respectively. The 
concentrations of Fab’-(CCE)1 and CCK in (CCK)9-P were 0.5 and 25 µM, respectively, 
for P 1 and C 1 in caspase 3 assay, and 1 and 25 µM, respectively, for all other 
experiments. P-Ctrl 1: a premixture of Fab’ (1 µM), CCE (1 µM), CCK (25 µM), and P-
NH2 (2.80 µM); P-Ctrl 2: a premixture of Fab’-(CCE)1 (1 µM) and P-NH2 (2.80 µM); P-
Ctrl 3: a premixture of Fab’ (1 µM) and (CCK)9-P (2.80 µM); C-Ctrl 1: Fab’ (1 µM) and 
CCE (1 µM) for 1 h, and then CCK (25 µM) and P-NH2 (2.80 µM); C-Ctrl 2: Fab’-
(CCE)1 (1 µM) for 1 h, then P-NH2 (2.80 µM); C-Ctrl 3: Fab’ (1 µM) for 1 h, then 
(CCK)9-P ([CCK]=25 µM/ [P-NH2]=2.80 µM). Results are presented as mean values ± 
standard deviation (n=3).  
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CCE-P should minimize the nonspecific binding to negatively charged cell surface. 
Another possible interfering factor is the steric hindrance from the glycocalyx layer, 
which may interfere with the transport of (CCK)9-P toward the CCE decorated cell. This 
might be overcome by inserting a spacer between the Fab’ and CCE, and hence CCE 
should be more accessible for subsequent self-assembly. 
        As observed, premixture of Fab’-(CCE)1 and (CCK)9-P demonstrated higher levels 
of apoptosis induction  than  the  consecutive  addition,  provided  other  conditions  were 
the same. This observation was believed to be a result of the multi-valency effect. The 
premixture resulted in coiled-coil mediated formation of conjugates containing several 
Fab’ fragments attached to one macromolecule resulting in the increase in their avidity, 
an observation in agreement with our previous data (21). 
        In further experiments, the systems were compared at the time intervals 
corresponding to maximum apoptosis, that is, 6 h for premixture and 24 h for consecutive 
addition. The extent of apoptosis could be increased by manipulating the concentration of 
the components. An increase in the Fab’-(CCE)1 concentration from 0.5 to 1 µM led to an 
increase in the amount of apoptotic cells from 21 to 32% in the consecutive addition ( as 
shown in Figure 3.12a). The results of annexin V (Figure 3.12b) and TUNEL (Figure 
3.12c) assays corroborated the efficacy of the system in the presence of FBS. Comparable 
levels of apoptosis induction (ca. 30%) were observed for consecutively added Fab’-
(CCE)1 (1 µm) and (CCK)9-P ([CCK]=25 µm), consecutively added 1F5 and GAM (ca. 
40%), and premixed Fab’-(CCE)1 and (CCK)9-P (ca. 40%). The apoptotic levels observed 
here were comparable to those found upon the exposure of Raji B cells to multivalent 
antibody conjugates: HPMA copolymers containing multiple Fab’ fragments (21), 
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dextran–antibody (rituximab) conjugates (26), and rituximab dimers (27). 
        Control experiments validated the hypothesis that the coiled-coil heterodimerization 
of CCE with CCK with concomitant cross-linking of the CD20 antigen is responsible for 
apoptosis induction. Different combinations of the building blocks (Table 3.1) of the 
binary systems were incubated with Raji B cells for 6 and 24 h for premixture and 
consecutive addition, respectively. The levels of apoptosis observed after the exposure of 
Raji B cells were very low and similar to those observed for untreated cells (Figure 3.12 
a–c, controls 1, 2, and 3). 
        Further optimization of the current system might result in even higher apoptosis 
levels. The factors can be explored include optimization of the concentration and the 
timing of consecutive addition of the components, the use of D-amino acid sequences, the 
design of shorter sequences, and the insertion of a spacer between Fab’ and the peptide. 
  
3.5. Conclusion 
        Several factors contributed to the successful design of this new drug-free therapeutic 
system: a) the use of the 1F5 antibody, the binding of which to CD20+ cells does not 
induce apoptosis: a secondary GAM antibody (28) is needed; b) the design of the CCE 
and CCK sequences (6): antiparallel heterodimer formation reduces the steric hindrance 
of the polymer chain during the binding of (CCK)9-P to Raji cells predecorated with CCE 
motifs and enhances the probability of “in-register” alignment of the CCE-CCK 
heterodimer; c) the HPMA copolymer employed for the conjugation of multiple copies of 
one of the peptides (CCK): HPMA copolymers have been widely used in drug-delivery 
systems (29, 30), and their biocompatibility has been proven in animal models (31-33) 
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and clinical trials (34); d) the choice of the CD20 antigen: CD20 is expressed on most 
NHL malignant cells as well as on normal B cells; however, it is not expressed on stem 
cells and mature plasma cells; consequently, normal numbers of B cells can be restored 
after treatment (35). 
        We have presented a new approach to apoptosis induction mediated by the 
biorecognition of coiled-coil-forming peptide segments on the cell surface. The fact that 
biorecognition of coiled-coils at the cell surface occurred in media containing 10% FBS 
indicates the specificity of the CCE–CCK interaction and bodes well for future in vivo 
experiments and for the development of efficient drug-free macromolecular therapeutics. 
The important feature of this design is the absence of low-molecular-weight cytotoxic 
compounds. The concept of drug-free macromolecular therapeutics could be expanded by 
using different components in the design. For example, the Fab’ fragment could be 
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 CHAPTER 4 
 
TREATMENT OF HUMAN B-CELL NON-HODGKIN’S  
LYMPHOMA IN SCID MICE BY DRUG-FREE  
MACROMOLECULAR THERAPEUTICS  
 
4.1 Summary 
        CD20 was found to be a reliable biomarker for non-Hodgkin’s lymphoma (NHL), 
expressed on more than 95% of the diseased B cells. Recently, our group successfully 
developed a drug-free macromolecular therapeutics, a binary system composed of 1) anti-
CD20 antibody fragment (Fab’) conjugated with CCE (a coiled-coil motif) and 2) 
polyHPMA copolymers grafted with multiple copies of CCK (another coiled-coil motif 
complementary to CCE). More importantly, we proved the concept that CCE-CCK 
heterodimerization into coiled-coil on cell surface could mediate the cross-linking of 
CD20 antigens and concomitantly induce clinically relevant magnitude of apoptosis of 
diseased lymphatic B cells. As a continuing effort, in vivo evaluation of such a binary 
system was conducted on a systemic NHL model on C.B-17 SCID mice. Preliminary 
results demonstrated that the current system could successfully suppress the proliferation 
and subsequently deplete inoculated human Burkitt’s Raji B cells after multiple-dose 




        Non-Hodgkin’s lymphoma (NHL) is among the top 10 most prevalent cancers in the 
United States; the projected new cases and death from NHL in 2010 are 65,540 and 
20,210, respectively (1). Pathogenesis analysis revealed that B-cell abnormality counts 
for 85% of the NHL incidences; in addition, more than 95% of the diseased B cells are 
bearing CD20 surface antigen (2, 3). The unique features of CD20 make it a reliable 
biomarker and a useful target for NHL: noninternalizing, noncirculating, and non-
shedding upon binding to antibodies (4).  
        Mechanism studies on rituximab, an FDA approved monoclonal antibody (mAb) for 
NHL treatment, demonstrated that direct apoptosis could be induced upon its binding to 
CD20 antigens (4, 5). Further exploration on this phenomenon led to the finding that 
(super) cross-linking of CD20 triggered the apoptotic pathway (6, 7). Following this 
track, researchers have employed secondary antibody (7) and dextran-antibody 
conjugates (8) to induce apoptosis of the diseased B cells. Due to the unique feature of 
CD20, expressed only on B cells but not plasma and hemapoietic stem cells (2, 3), the 
reestablishment of blood homeostasis is possible after the treatment. 
        However, mounting incidences of severe side effects after rituximab treatment have 
been reported (4, 9, 10). Accumulating evidence points the Fc fragment/region of the 
antibody, which not only mediates the antibody-dependent cellular cytotoxicity (ADCC) 
and complement-dependent cytotoxicity (CDC) during the treatment but also mediates 
these side effects (11-13). These findings are diverting further treatment modalities to 
focus on direct apoptosis induction.                     
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        Based on the aforementioned lines of evidence, our group developed a novel drug-
free macromolecular therapeutic system to combat B-cell NHL (14). This binary system 
was composed of a conjugate of Fab’ fragment of anti-CD20 mAb (1F5) and CCE, and a 
polyHPMA copolymer grafted with multiple copies of CCK. CCE and CCK were de 
novo designed coiled-coil forming peptides containing five heptads that could exclusively 
self-assemble into heterodimers in anti-parallel orientation; the resulted coiled-coil would 
function as an in situ cross-linker mediating the recognition of the two components (15). 
Here only Fab’ fragment was employed in the design so that any Fc fragment related side 
effects would be diminished. The multivalent construction of polyHPMA graft 
copolymer would provide the platform for cross-linking CD20 antigens. In vitro study on 
human Burkitt’s lymphoma Raji cells showed that this binary system could induce 
clinically relevant level of apoptosis (30-50%) (14).  
        Here in vivo evaluation of this drug-free macromolecular therapeutics is reported. A 
systemic NHL model was established in C.B-17 SCID mice by i.v. injection of Raji cells, 
then different treatments were applied. Using the onset of hind-limb paralysis as a study 
end-point, we observed significant extension of paralysis-free duration after treatments. 
Bone marrow from different subjects was analyzed to examine the presence of residual 
Raji cells via fluorescently labeled anti- CD10 and CD19 mAb staining.  
 
4.3. Materials and methods 
4.3.1. Conjugate preparation 
        (Fab’)1-CCE and (CCK)9-P were synthesized as previously reported (14), and the 
detailed synthetic schemes were described in Figure 3.3. For Fab’ conjugate: 1F5 anti-
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CD20 antibody was prepared using the anti-CD20 hybridoma clone 1F5, and then 
consecutively digested to F(ab’)2 and reduced to Fab’ by lysyl endopeptidase (Wako 
Chemicals USA, Richmond, VA) and TCEP (Thermo Scientific, Waltham, MA), 
respectively; finally CCE capped with maleimido group was conjugated to Fab’ via 
thioether bond. The graft copolymer was synthesized using a polymeranalogous strategy: 
first HPMA and N-(3-aminopropyl)methacrylamide (Ma-NH2) were copolymerized via 
free radical polymerization, then SMCC was employed to convert the side-chain amino 
groups into maleimido groups, and finally CCK peptides were grafted onto the polymer 
backbone through the reaction between thiol and maleimido groups. All synthesis steps 
were monitored with various techniques (e.g., RP-HPLC, SEC, SDS-PAGE). The number 
of CCK peptides in the final graft copolymer was determined as 8.94 via amino acid 
analysis, so the construct was designated as (CCK)9-P.  
 
4.3.2. Cell line and systemic NHL SCID mouse model 
        Human Burkitt’s B-cell NHL Raji cells (ATCC, Manassas VA) were cultured as 
described before (14). The cells were maintained in RPMI-1640 medium supplemented 
with 10% fetal bovine serum (FBS) at 37 oC in a humidified atmosphere of 5% CO2. 
Cells at the exponential growth phase were used for mice inoculation. 
        Female C.B-17 SCID mice (~6 weeks old) (16-18) were purchased from Charles 
River Laboratories (Wilmington, MA) and maintained following the protocol approved 
by the Institutional Animal Care and Use Committee (IACUC) from University of Utah. 
Following the model described by Ghetie and colleagues (19), mice with body weight 
around 20 g were intravenously injected with 4×106 Raji cells in 200 µL normal saline 
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(N.S.) via the tail vein. Our pilot study demonstrated the untreated mice could develop 
hind-limb paralysis around 3 weeks postinnoculation, a proof of successful model 
establishment observed by other researchers as well (16, 19, 20). 
 
4.3.3. Treatments and follow-ups  
        Inoculated mice were divided into five groups: Ctrl, control group without 
treatment; ConSingle, consecutive administration of single dose; PreSingle, premixed 
administration of single dose; ConMultiple, consecutive administration of multiple (3) 
doses; and PreMultiple, premixed administration of multiple (3) doses. Here consecutive 
administration involved the i.v. injection of Fab’-(CCE)1 first and 1 h later the (CCK)9-P 
conjugate was applied via the same route; while in the premixed administration, the two 
conjugates were first mixed outside the body for 1 h, and then injected via the tail vein. 
For single-dose groups, conjugates were administered 24 h postinoculation; for multiple-
dose groups, conjugates were applied 24, 72, 120 h postinoculation. The doses in each 
treatment for (Fab’)1-CCE and (CCK)9-P were 50 µg/20 g and 324 µg/20 g, respectively. 
This combination ensured the molar ratio between CCE and CCK to be 1:25 (14).  
        Postoperation monitoring was exercised at least once a day. Major aspects 
monitored were body weight, physical appearance (e.g., hunched back, piloerection), 
food intake and hind-limb paralysis. Animals were sacrificed at signs of sickness, such as 
the onset of hind-limb paralysis, >20% of body weight loss, and if mice survived for 





4.3.4. Residual Raji cell analysis  
        Immediately after the sacrifice, femurs were harvested from the subject and purged 
with cold PBS to collect bone marrow cells. Then 5 volumes of cold red blood lysing 
solution was added into 1 volume bone marrow cell suspension; the mixture was 
incubated for 2-3 min at room temperature and centrifuged to remove cell debris. After 
washing with cold washing buffer once, the bone marrow cells were divided into three 
tubes (~50 µL each) suspended again by cold washing buffer.  One tube was spared as 
control, and the rest two were stained by Raji cell specific primary antibodies: R-
phycoerythrin (PE) mouse anti-human CD10 (mouse IgG1, κ isotype) and 
allophycocyanin (APC) mouse anti-human CD19 (mouse IgG1, κ isotype). Both 
antibodies were purchased from BD Biosciences (San Jose, CA). Twenty microliter 
fluorescently labeled antibody (CD10 or CD19) was added and incubated with processed 
bone marrow cells for 40 min at 4 oC in the dark. Finally, flow cytometry was employed 
to identify the residual Raji tumor cells.     
 
4.4. Results and discussion 
4.4.1. Therapy studies of systemic NHL in SCID mice 
        After inoculation of 4×106 Raji cells, mice developed hind-limb paralysis within 22 
days if no treatment was applied. This observation was in good agreement with results 
published by other groups (17, 20-23). However, the tumor-bearing mice treated with 
single- or multiple-dose experienced a significantly extended paralysis-free duration 
(p<0.05). In our preliminary experiments, three mice in each group were recruited as 




Figure 4.1. Therapeutic efficacy of macromolecular therapeutics on systemic Raji cell induced NHL in SCID mice (n=3/group). 
Dosages in each treatment were 50 µg/20 g and 324 µg/20 g for Fab’-(CCE)1 and (CCK)9-P, respectively. Single treatment was 
applied 24 h after i.v. inoculation of 4×106 Raji cells. Mutiple treatments were administrated 24, 72 and 120 h postinoculation. 
Significant extension of paralysis-free duration was observed after single treatments (PreSingle and ConSingle) and multiple 
treatments (PreMultiple and ConMultiple) (p<0.05) in comparison to untreated controls (Ctrl). Multiple (three doses) treatments did 
produce long-term survivors that survived for 100 days without paralysis. PreSingle, premixed administration for single dose; 
ConSingle, consecutive injections for single dose; PreMultiple, premixed administration for three doses; ConMultiple, consecutive 
injections for 3 doses.  
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22 to 35 days; while three-dose treatment produced long-term survivors (one out of three 
in PreMultiple group, and two out of three in ConMultiple group) that survived for 100 
days without paralysis. But the two modalities of administration, consecutive injection 
and premixture, did not differ significantly in neither single- nor multiple-dose 
treatments. This was not unexpected since we proved previously that the presence of 
protein did not compromise the molecular biorecognition of CCE and CCK motifs (14).  
 
4.4.2. Analysis of residual Raji cells in bone marrow 
         Besides CD20, CD10 and CD19 are another two specific cell surface antigens for 
human Burkitt’s lymphoma (24, 25). Upon binding to the primary antibodies, they intend 
to be internalized although with different kinetics; but they do not shed into the 
extracellular space (26). These features make them excellent diagnostic tools to identify 
the presence of B cells. In our study, two fluorescently labeled mouse anti-human 
antibodies were employed to detect the residual Raji cells in the bone marrow: PE mouse 
anti-human CD10 and APC mouse anti-human CD19.  
        As shown in Figure 4.2, the presence of residual Raji B cells was confirmed in 
untreated mice, and also in the mice that received single-dose treatment; however, no 
residual malignant B cells were detected in the survivors treated with three doses. Here 
the mice were either sacrificed at the onset of hind-limb paralysis or survived for >100 
days. Apparently, the multiple treatments with 48 h apart managed to deplete Raji cells 
(27); while the single treatment only slowed down the tumor progression. The necessity 
for multiple doses was possibly related to the short doubling time (20-24 h) of this cell 

























Figure 4.2. Evaluation of residual Raji B cells in the bone marrow after different 
treatments. Bone marrow cells were stained by fluorescently labeled mAbs: PE-CD10 















full development of paralysis. It is foreseeable that a higher dosage can deplete the 
diseased cell after only one administration.    
        In comparison to the untreated mice, the flow cytometry profiles of the mice after 
single treatment did not show a significant difference. This is reasonable because the 
hind-limb paralysis was eventually caused by the flourishing of Raji cells in both 
scenarios. With more animals in each group, the dynamics (proliferation/depletion) of 
diseased B cells inside the mice can be revealed by examining the bone marrow after 
various durations posttreatment (e.g., 7, 21, and 42 days). Corresponding results will 
guide us for further optimization of the current treatment.  
 
4.5. Conclusion 
        We designed a novel drug-free macromolecular therapeutics, in which molecular 
biorecognition between a pair of complementary coiled-coil forming peptides (CCE and 
CCK) was introduced as the key driving force to cross-link CD20 surface antigens. 
Cross-linking events on the cell surface subsequently triggered apoptosis of the diseased 
cells to a clinically relevant magnitude (14). Current in vivo evaluation further 
demonstrated that this binary system is a promising macromolecular therapeutics to treat 
B-cell NHL. Our preliminary results demonstrated that after three-dose treatment, the 
diseased B cells could be depleted and the animals could survive up to 100 days without 
paralysis. Following optimizations may improve the therapeutic efficacy of this system: 
more uniform polymer construct, dosage adjustment, and dosing frequency. Long-term 
study is also necessary to detect the disease relapse, resistance (12) and side effects (4), 
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which are typically affiliated with rituximab treatment. Survival study, bone marrow 
analysis and pathologic examination on the harvest organs are still ongoing. 
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SUMMARY AND FUTURE WORK 
 
5.1. Summary 
        The experiments described in this dissertation were designed to accumulate basic 
knowledge of using coiled-coil protein folding pattern in the construction of smart 
biomaterials. To achieve this goal, two scenarios were created: to construct HPMA 
copolymers grafted with coiled-coil forming motifs facilitating the hybrid hydrogel self-
assembly; to develop a drug-free macromolecular therapeutics composed of two 
conjugates in which heterodimerization of two coiled-coil motifs would mediate the 
cross-linking of cell surface antigens. 
        The first scenario involved the synthesis of HPMA graft copolymers containing 
coiled-coil motifs with different lengths, and the evaluation of the structural and 
environmental factors on gel formation. The second one involved the construction of two 
conjugates: a multivalent HPMA copolymer grafted with coiled-coil forming peptides, 
and an anti-CD20 antibody (Fab’) fragment conjugated with another coiled-coil forming 
peptide. Due to the multivalency effect, the self-assembly of these conjugates could 
cross-link CD20 surface antigens on B cell surface and concomitantly induce apoptosis. 
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          This dissertation has two major sections covering corresponding scenarios 
mentioned above. In the first section (Chapter 2), a novel macromonomer free radical 
copolymerization strategy was adopted to “glue” HPMA and polymerizable coiled-coil 
sequences together forming graft copolymers. Sequences containing different numbers 
(namely 3, 4, and 5) of heptads were synthesized via manual solid phase peptide 
synthesis, and further incorporated into different copolymers. The results indicated that 
the homo-oligomerization among coiled-coil peptides could function as physical cross-
linkers interconnecting HPMA copolymers; however, at least four heptads were needed 
to sufficiently mediate the gel formation. Also found was that copolymer concentration 
and environment temperature could greatly impact the gelation process. Circular 
dichroism (CD) spectroscopy, dynamic light scattering (DLS), and microrheology were 
proved to be useful tools in gauging different aspects of the resulted hybrid materials. 
        The other section covered Chapters 3 and 4 related to biorecognition between a pair 
of complementary coiled-coil motifs in biological systems. In Chapter 3, a new concept 
was proposed to induce apoptosis of diseased B cells to combat non-Hodgkin’s 
lymphoma (NHL). The rationale was based on the following facts: CD20 is a reliable 
surface biomarker for B-cell NHL and the cross-linking of CD20 surface antigens can 
induce the direct death (apoptosis) of the malignant lymphatic cells. To this end, a 
polymer analogous strategy was employed to synthesize an HPMA graft copolymer 
containing multiple copies of CCK (a coiled-coil forming motif); and two-step digestion 
in tandem with direct conjugation was used to prepare the second component in this 
binary system: Fab’ fragment of anti-CD20 1F5 antibody conjugated with CCE 
(complementary coiled-coil forming motif). In vitro experiments successfully 
	   167	  
demonstrated the colocalization of the two conjugates on Raji B cell surface and efficient 
apoptosis induction of the same cell line (30-50 %). Chapter 4 was a continuing effort to 
evaluate the in vivo efficacy of the current system on a systemic NHL murine model. In 
the first smaller set of studies, three C.B-17 SCID mice in each group were recruited and 
corresponding groups were treated with either single or multiple (3) dose of the 
therapeutics. Preliminary results showed satisfactory therapeutic effect: single treatment 
could significantly extend the paralysis-free duration, and multiple treatments could help 
animals survive more than 100 days being disease-free; more importantly, the B cells 
could be depleted after multiple treatments, as demonstrated by the bone marrow 
analysis. Currently, a bigger set (n=7 per group) of studies are undergoing, available 
results indicated the same trends as reported in Chapter 4.  
        The concept of incorporating protein folding patterns opens another door in building 
smart biomaterials. The intriguing features of self-arrangements of the folding motifs into 
regular structure attract great attention to de novo designing such motifs and to use them 
as an internal driving force leading to various biofunctions. Recent progress proved the 
possibility of combining peptide/protein domains with synthetic materials. Moreover, the 
achieved hybrid materials can possess unprecedented properties as a result of 
superimposing the advantages of both ingredients while minimizing their disadvantages. 
This dissertation focused on the aspect of using coiled-coil folding motifs as building 
block for new biomaterials. We elucidated the structure-property relationship of HPMA 
copolymers grafted with coiled-coil motifs regarding the structural and environmental 
factors impacting their self-assembly into hydrogels; more importantly, we proved the 
unique molecular biorecognition between the peptides could be extended beyond 
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biomaterials and applied to a living system to mediate a biological process. These insight 
views present us a bright future in creating peptide/protein-based hybrid materials with a 
broad spectrum of biophysical properties.  
     
5.2. Future work 
        The current results laid a foundation for the development of hybrid hydrogels whose 
self-assembly is mediated by coiled-coil formation, and a promising drug-free 
macromolecular therapeutics for non-Hodgkin’s lymphoma. However, shorter peptide 
sequences would dramatically reduce the synthesis workload and refinement of the 
hybrid constructs would provide further details in rational design in a hopeful manner 
leading to more potent biofunctions. With these in mind, we proposed the following 
investigations for the near future.  
 
5.2.1. Design of short coiled-coil motifs to effectively  
mediate cross-linker formation 
        The primary goal to optimize the coiled-coil forming peptides is to achieve 
sufficient cross-linking while consuming the least materials. Currently, the hybrid 
hydrogel formation described in this dissertation was mediated by homo-oligomerization 
of coiled-coil motifs, which lacks detailed control over the oligomer composition and the 
orientation (parallel or anti-parallel) of helical alignment. In other words, the resulting 
hydrogels were heterogeneous and there was a strong steric hindrance to overcome 
during assembly. In the macromolecular therapeutics, a pair of complementary coiled-
coil forming peptides was engineered to adopt an anti-parallel orientation and indeed they 
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did show excellent association ability at concentrations as low as 0.1 wt.% (1). However, 
the sequences were relatively long (5 heptads) and needed to be truncated to improve the 
synthesis efficiency.  
        Therefore, a possibly ideal supercoil in our case should consist of exclusively 
heterodimerized coiled-coil motifs with the least number of heptads and “in-register” 
(full overlap) alignment in an anti-parallel orientation. To fulfill this requirement, we 
need to de novo design a pair of short, self-repulsive, but mutually complementary 
coiled-coil forming peptides, so that they only self-associate into anti-parallel 
heterodimers and subsequently reduce the steric hindrance during graft-copolymer self-
assembling. The heptad number can be reduced to 3 (2) while maintaining strong 
association constant for efficient cross-linking (3). Although coiled-coil motifs containing 
only two heptads were designed, the rationale and binding constants were not fully 
revealed by the authors (4). Strategies can be adopted to ensure the anti-parallel 
heterodimerization include salt bridge across the interface and polar residues in the 
hydrophobic core. Various algorithms can be employed to facilitate rational design, as 
summarized in Chapter 1. CD spectroscopy and analytical ultracentrifugation (AUC) are 
useful to examine the association constant and confirm the oligomerization state, 
respectively. Fluorescence resonance energy transfer (FRET) is a useful technique to 
visualize the degree (partial or full) of overlap of the pair (5). As a result, a new 
generation of hybrid materials will possess higher efficiency of self-assembly and better 
defined architecture.  
 
 
	   170	  
5.2.2. Optimization of the polymer backbone 
        The backbones of graft copolymers discussed in this dissertation had wide molecular 
weight distributions and relatively big variation from batch to batch. Consequently, the 
control over the detailed structure of the resulted hydrogels and therapeutics was 
compromised. These are closely related to the nature of the synthetic method employed: 
free radical copolymerization.   
        Reversible fragmentation-addition chain-transfer (RAFT) polymerization and atom 
transfer radical polymerization (ATRP) are generally good synthetic strategies to control 
molecular weight and weight distribution. In our case, random copolymers need to be 
generated using these methods. A detailed kinetic screening of individual monomers has 
to be conducted before plunging into copolymerization, for example in RAFT (6); even 
though, the difference in monomer reactivity may still lead to lower-than-expected 
incorporation rate of certain monomers and heterogeneity of the final copolymer is also a 
possible concern. For instance, HPMA and polymerizable coiled-coil motifs are very 
different monomers regarding their size, (secondary) structure, possible self-association, 
and consequently reactivity ratio (7); hence, heterogeneous copolymer (composition drift) 
is possible outcome even synthesized via RAFT and ATRP. Therefore, the most available 
strategy is the polymeranalogous pathway: to first synthesize polymer precursors 
composed of monomers of similar reactivity, and then to graft/conjugate other functional 
molecules to achieve the final construct.   
        Another remedy is to prepare uniform homopolymer segment of low molecular 
weight using the aforementioned synthetic methods, and then “glue” them together via 
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bi-/tri-functional linkers. Other components may be imbedded in the linkers already or 
can be grafted later via chemical modifications to these “joints”.  
        The clearance of the polymeric constructs post application should be also 
considered. For example, renal clearance threshold for polyHPMA is 40 kDa and bigger 
segments will be retained and accumulated inside the body. To facilitate renal clearance, 
biodegradable polymer backbone can be introduced. Besides traditional biodegradable 
copolymers (8), our group recently developed a new strategy to manufacture such 
structures: short polyHPMA segments are “threaded” by enzymatically cleavable linker 
(GFLG) via click chemistry into long well defined polymer backbone. Further 
modifications to such backbone may allow for the construction of functional graft 
copolymers.       
 
5.2.3. Further evaluation and optimization of the  
structure-property relationship 
        In Chapter 2, we spent great effort to scrutinize the structure-property relationship of 
hybrid copolymers. To achieve the optimal efficiency of hydrogel formation, more 
factors need to be examined, such as the number of grafts in each copolymer molecule, 
the distance between grafts, environmental ionic strength and pH. For different 
applications, the size and composition polymer backbone may also need to be optimized.  
        The same requirements apply to the molecular therapeutics described in Chapters 3 
and 4. For instance, the graft distance in the copolymer can be optimized according to the 
density of CD20 on B cell surface; a balance between graft number and polymer 
backbone size needs to be reached so that efficient multivalency effect could be 
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preserved while minimizing the copolymer accumulation. Appropriate spacers may be 
incorporated in both conjugates to minimize the steric hindrance during biorecognition.          
 
5.2.4. Exploring possible applications of the novel hybrid hydrogels 
        The ultimate goal for designing smart hybrid copolymers is to satisfy actual 
biomedical needs. The unprecedented properties (e.g., stimuli-responsiveness and tunable 
microstructure) of the novel hybrid hydrogels render them good candidates for various 
applications. 
        As drug carriers, they can work as multifunctional vehicles: 1) to deliver cargos 
locally or systemically to the site of reaction; 2) to protect cargos from premature 
digestion; 3) to control the cargo release in an expected fashion upon 
signaling/stimulation. Model molecules and even drugs should be introduced and their 
release profiles would provide detailed guidance for the optimization of such materials.  
Of course, modifications to the components of the hybrid copolymers should be 
individualized toward different requirements.  
        Besides delivery of therapeutic agents, these novel smart materials can be also used 
as biosensors to detect trivial environmental changes. With appropriate adjustment of 
cross-linking density and mechanical strength, they can be good 3-D matrix to facilitate 
in situ cell culture and proliferation in tissue repair and regeneration.  
 
5.2.5. Immunogenicity of macromolecular therapeutics 
        Fab’ fragment from murine 1F5 is believed to be immunogenic in human body (9, 
10). In addition, non-natural peptides (CCE and CCK) in both conjugates are possibly 
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immunogens as well (11, 12). Thus it is necessary to carefully study their 
immunogenicity, especially in hope of developing real-life therapeutics. The well-
established methods for immunogenicity study include macrophage activation (13) by 
monitoring the release of various cytokines (e.g., TNF-α, IL 1, IL-6) (14, 15) and reactive 
oxygen species (ROS) (16, 17), electrochemoluminescence, fluorescence activated cell 
sorting (FACS), surface plasmon resonance (SPR), and radio immunoprecipitation assays 
(RIA) (18).  
        To minimize immunogenicity, the murine Fab’ fragment can be replaced by fully 
humanized anti-CD20 antibody Fab’ fragment (18). GA 101, the latest human anti-CD20 
mAb, is a promising candidate for this purpose (19). Coiled-coil peptides can be 
synthesized using only D-amino acid residues to avoid possible interference on their 
biorecognition, and to probably lower the immunogenicity as well. However, one has to 
answer the following question first: are D-peptides immunogens or not (20, 21)?    
        Needless to say, the immune response solicited by the hybrid hydrogels should be 
also examined prior to biomedical use. Same strategies and methods could be employed 
in doing so.  
 
5.2.6. Dosage and interval optimization of the binary system 
        Similar to other members in the pretargeting family, the binary system described in 
Chapter 3 and 4 is facing a big challenge – optimization of the dosage and injection 
interval (22). But there are two unique features distinguishing this system from others. 
First, the targets, lymphatic B cells, are located in circulation; second, there is no 
cytotoxic small molecular anticancer drug used. Therefore, we just need to ensure that 
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sufficient Fab’-CCE conjugate is administered to decorate CD20+ B cells and no chasing 
step is needed. Since excess conjugate is nontoxic and will be digested eventually due to 
its protein nature.  
        For optimizing the dosage of Fab’-CCE and injection interval, two major issues 
need to be considered. First, enough Fab’-CCE and time have to be given for saturating 
the diseased B cells in circulation and in vitro cell staining experiments can be a good 
reference to propose suitable dosage and time frame. Second, CD20 is not strictly non-
internalized upon binding to antibody, but within the first 18 h only 5-10 % is slowly 
internalized (23). Thus the injection interval for our system should be in the range of 0-18 
hours to guarantee efficient cross-linking, in contrast to the intervals (~ a few days) of 
other pretargeting systems (22). 
        Currently, a 25-time molar excess of CCK motif in CCK-P conjugate is employed 
during the treatment. More in vitro and in vivo experiments may be designed to further 
optimize this ratio to either improve the therapeutic effect or save materials.  
               
5.2.7. In vivo studies 
        Here we reported the preliminary in vivo studies, in which only two administration 
regimens were adopted – single- and multiple- treatments with only one dosage involved. 
To maximize the therapeutic efficiency, optimization for dosage and treatment frequency 
is necessary to be carried out, as discussed in 5.2.6. A time-dependence profile of the 
therapeutic effect needs to be delineated as well: depletion degree of diseased cells (%) 
vs. time post treatment. Studies on biodistribution, metabolism, and elimination of the 
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conjugates are also indispensible for the improvement of such therapeutics. Additionally, 
long-term studies for possible side effects and toxicity should be performed.     
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